08/765,026
attachment to
Paper #6

```
*                                                                    *
  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
FILE 'USPAT' ENTERED AT 15:48:22 ON 26 DEC 1997

  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
  *                W E L C O M E   T O   T H E                      *
  *          U. S.   P A T E N T   T E X T   F I L E                *
  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *

=> s adenovir? and superoxide
          2357 ADENOVIR?
          2027 SUPEROXIDE
L1         113 ADENOVIR? AND SUPEROXIDE

=> s l1 and dismutase
          1056 DISMUTASE
L2          95 L1 AND DISMUTASE

=> s adenoviral vector? and superoxide dismutase
           141 ADENOVIRAL
         62137 VECTOR?
            65 ADENOVIRAL VECTOR?
                 (ADENOVIRAL(W)VECTOR?)
          2027 SUPEROXIDE
          1056 DISMUTASE
          1032 SUPEROXIDE DISMUTASE
                 (SUPEROXIDE(W)DISMUTASE)
L3           6 ADENOVIRAL VECTOR? AND SUPEROXIDE DISMUTASE

=> d l3,1-6,cit,ab

1.  5,670,488, Sep. 23, 1997, Adenovirus vector for gene therapy; Richard
J. Gregory, et al., 514/44; 424/93.2; 435/320.1; 935/62 :IMAGE AVAILABLE:

US PAT NO:      5,670,488 :IMAGE AVAILABLE:            L3: 1 of 6

ABSTRACT:
Gene Therapy vectors, which are especially useful for cystic fibrosis,
and methods for using the vectors are disclosed.

2.  5,641,662, Jun. 24, 1997, Transfection of lung via aerosolized
transgene delivery; Robert James Debs, et al., 435/172.1; 128/200.14,
200.24; 424/450; 435/172.3, 320.1; 436/71; 514/44; 536/24.1 :IMAGE
AVAILABLE:

US PAT NO:      5,641,662 :IMAGE AVAILABLE:            L3: 2 of 6

ABSTRACT:
Methods and compositions for producing a mammal capable of expressing an
exogenously supplied gene in cells of the airway are disclosed. Lipid
carrier-nucleic acid complexes are prepared then delivered via aerosol to
the lung airway. The invention provides a direct method for transforming
pulmonary cells as a means for treating disorders of the lung as for
providing a means for delivering substances systematically following
expression in the lung.

3.  5,599,712, Feb. 4, 1997, Protection from ionizing irradiation or
chemotherapeutic drug damage by in vivo gene therapy; Joel S.
Greenberger, 435/267; 424/93.2, 93.21; 435/320.1; 514/44 :IMAGE
```

AVAILABLE:

US PAT NO: 5,5[redacted]12 :IMAGE AVAILABLE: 3 of 6

ABSTRACT:
A method of protecting a subject against an agent that elicits production of toxic free radicals, superoxide anions, or heavy metal cations in the subject consisting of the in vivo administration to the subject of a polynucleotide encoding a protein that is transiently expressed in said subject. The transiently expressed protein is capable of neutralizing or eliminating the toxic free radicals, superoxide anions or heavy metal cations that are elicited by the agent. This method is particularly useful in protecting cancer patients against the damaging effects of ionizing radiation and chemotherapeutic drugs.

4. 5,571,797, Nov. 5, 1996, Method of inducing gene expression by ionizing radiation; Tsuneya Ohno, et al., 514/44; 424/1.11, 1.49, 1.61, 1.65, 1.69, 93.2, 93.21, 450; 435/69.1, 69.5, 172.3, 320.1; 536/24.1; 935/6, 34, 59, 62 :IMAGE AVAILABLE:

US PAT NO: 5,571,797 :IMAGE AVAILABLE: L3: 4 of 6

ABSTRACT:
The present invention provides a method for delivering ionizing radiation to specific tissues, resulting in the activation of a DNA molecule comprising a radiation responsive enhancer-promoter operatively linked to an encoding region that encodes at least one polypeptide. The radiation source may be will generally be in the form of a radionuclide, capable of gamma or beta emissions. Processes for regulating polypeptide expression and inhibiting tumor growth using such DNA molecules are also provided.

5. 5,552,309, Sep. 3, 1996, Use of polyols for improving the introduction of genetic material into cells; Keith L. March, 435/172.3; 424/93.1, 93.2, 426; 435/235.1, 320.1; 514/44; 935/57 :IMAGE AVAILABLE:

US PAT NO: 5,552,309 :IMAGE AVAILABLE: L3: 5 of 6

ABSTRACT:
A process for introducing an expression vehicle (e.g., plasmids, retroviral vectors, **adenoviral vectors**) into cells, which comprises contacting the cells with the expression vehicle and a polyol. The polyol may be a polyoxalkylene block copolymer, such as a polyoxypropylene-polyoxyethylene block copolymer. The use of the polyol provides for greater efficiency of transduction of the expression vehicle.

6. 5,496,731, Mar. 5, 1996, Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy; Hong-Ji Xu, et al., 435/320.1; 514/44; 536/23.5 :IMAGE AVAILABLE:

US PAT NO: 5,496,731 :IMAGE AVAILABLE: L3: 6 of 6

ABSTRACT:
The present invention relates to a broad-spectrum tumor suppressor gene and the protein expressed by that gene in appropriate host cells. The protein is a second in-frame AUG codon-initiated retinoblasoma protein of about 94 kD relative molecular mass. The present invention also relates to methods of treating a mammal having a disease or disorder characterized by abnormal cellular proliferation, such as a tumor or cancer and methods of treating abnormally proliferating cells, such as tumor or cancer cells. Treatment is accomplished by inserting a host cell compatible p94.sup.RB expression vector or an effective amount of p94.sup.RB protein into a cell or cells in need of treatment.

=> d kwic,1

DRAWING DESC:

DRWD(22)

FIGS. 17A and 17B show the plasmid construction for a second generation **adenoviral vector** (Ad2E4ORF6).

DETDESC:

DETD(27)
Second Generation **Adenoviral Vectors**

DETDESC:

DETD(28)

Adenoviral vectors currently in use retain most (.gtoreq.80%) of the parental viral genetic material leaving their safety untested and in doubt. Second-generation. . .

DETDESC:

DETD(32)

In . . . deliver CFTR in conjunction with other genes such as anti proteases (e.g., antiprotease alpha-1-antitrypsin) tissue inhibitor of metaloproteinase, antioxidants (e.g., **superoxide dismutase**), enhancers of local host defense (e.g., interferons), mucolytics (e.g., DNase); and proteins which block inflammatory cytokines.

DETDESC:

DETD(36)

The . . . may prove useful is in the development of a gene therapy vector encoding CFTR. As described above, the first generation **adenoviral vector** approaches the maximum packaging capacity for viral DNA encapsidation. As a result, this virus grows poorly and may occassionaly give. . .

DETDESC:

DETD(37)

In addition, by expressing only ORF6 of E4, these second generation **adenoviral vectors** may be safer for use in gene therapy. Although ORF6 expression is sufficient for viral DNA replication and late protein. . .

DETDESC:

DETD(108)

In summary, a mild, transient, pulmonary inflammatory response appears to be associated with the intratracheal administration of the described doses of **adenoviral vector** in the Syrian Hamster.

DETDESC:

DETD(109)

A . . . spread of ineffective viral vectors to organs outside of the

lung and the antibody response of the animals to the **adenoviral vector**. In this st[redacted]e three treatment groups (vehi[redacted] control, low dose virus, hi[redacted]se virus) each contained 12 anim[redacted]. Animals. . .

DETDESC:

DETD(111)

Studies of recombinant adenovirus are also underway in primates. The goal of these studies is to assess the ability of recombinant **adenoviral vectors** to deliver genes to the respiratory epithelium in vivo and to assess the safety of the construct in primates. Initial. . .

DETDESC:

DETD(233)

Construction and Packaging of Pseudo **Adenoviral Vector** (PAV)

DETDESC:

DETD(237)

For . . . desirable to generate significant quantities of PAV virion free from contaminating helper virus. The primary advantage of PAV over standard **adenoviral vectors** is the ability to package large DNA inserts into virion (up to about 36 kb). However, PAV requires a helper. . .

DETDESC:

DETD(246)

An **adenoviral vector** is prepared as described in Example 7 while substituting the PGK promoter for the Eta promoter.

DETDESC:

DETD(248)

An **adenoviral vector** is prepared as described in Example 11 while substituting the PGK promoter for the Ad2 major late promoter (MLP).

CLAIMS:

CLMS(1)

We claim:

1. An **adenoviral vector** comprising an adenovirus genome from which one or more of the E4 open reading frames has been deleted, but retaining. . .

CLAIMS:

CLMS(5)

5. The **adenoviral vector** of claim 1 in which open reading frame 6 of the E4 region is retained in the adenovirus genome.

CLAIMS:

CLMS(6)

6. The **adenoviral** [redacted]**tor** of claim 1 in which open rea frame 3 of the E4 region is retained in the adenovirus genome.

CLAIMS:

CLMS(7)

7. The **adenoviral vector** of claim 1 wherein the DNA sequence encodes cystic fibrosis transmembrane regulator protein.

CLAIMS:

CLMS(8)

8. The **adenoviral vector** of claim 2 wherein the DNA sequence encodes cystic fibrosis transmembrane regulator protein.

CLAIMS:

CLMS(9)

9. The **adenoviral vector** of claim 3 wherein the DNA sequence encodes cystic fibrosis transmembrane regulator protein.

CLAIMS:

CLMS(10)

10. The **adenoviral vector** of claim 3 wherein the DNA sequence is inserted into the deleted Ela and Elb regions of the adenoviral genome.

CLAIMS:

CLMS(11)

11. The **adenoviral vector** of claim 5 wherein the DNA sequence encodes cystic fibrosis transmembrane regulator protein.

CLAIMS:

CLMS(12)

12. The **adenoviral vector** of claim 6 wherein a cytomegalovirus promoter is operably linked to the DNA sequence of interest.

CLAIMS:

CLMS(13)

13. . . . to airway epithelial cells of a cystic fibrosis patient comprising administering directly to airway epithelial cells of the patient an **adenoviral vector**, said vector comprising an adenovirus genome from which one or more E4 open reading frames has been deleted, but retaining. . .

=> d kwic,2

US PAT NO: 5,641,662 :IMAGE AVAILABLE: L3: 2 of 6

SUMMARY:

BSUM(7)

Retroviruses, . . . intratracheal (IT), intravenous, intraperitoneal, intramuscular, and [redacted]rterial injection. Expression [redacted] introduced genes, either comp[redacted]d to cationic vectors or packaged [redacted] **adenoviral vectors** has been demonstrated in the lungs of rodents after IT instillation. However, IT injection is invasive and produces a non-uniform. . .

DETDESC:

DETD(22)

Examples of beneficial therapeutic nucleic acid sequences are those encoding molecules have **superoxide dismutase** activity or catalase activity to protect the lung from oxidant injury; endothelial prostaglandin synthase to produce prostacyclin and prostaglandin E2;. . .

DETDESC:

DETD(72)

Genes . . . prevention of lung damage due to degenerative lung disorders caused by smoking and other environmental agents. For example, genes encoding **superoxide dismutase** (SOD) or catalase, as well as .alpha.-1 antitrypsin, will be particularly useful for this purpose. These gene sequences are known.. . .

=> d kwic,3

US PAT NO: 5,599,712 :IMAGE AVAILABLE: L3: 3 of 6

SUMMARY:

BSUM(6)

Several . . . and heavy metal cations have been identified. Induction or elevated activities of each of metallothionein (MT), gamma-glutamyl transpeptidase (.gamma.-GTP) and **superoxide dismutase** (SOD) are known to provide resistance to ionizing radiation damage in vitro. Since these proteins function intracellularly to scavenge free. . . continual levels of the intracellular quantities required to furnish protection against ionizing radiation or an anticancer agent. Furthermore, if metallothionein, **superoxide dismutase** or gamma glutamyl transpeptidase proteins are administered to cells extracellularly, they may be rapidly degraded by proteases and fail to function intracellularly. No method for providing functional intracellular therapeutic levels of metallothionein, **superoxide dismutase** or gamma glutamyl transpeptidase to normal tissues in vivo is known.

SUMMARY:

BSUM(12)

Another object of the present invention is to provide intracellular therapeutic quantities of metallothionein, **superoxide dismutase** and/or gamma glutamyl transpeptidase in normal tissues in vivo adequate to furnish protection against ionizing radiation or an anticancer agent.

SUMMARY:

BSUM(14)

In . . . proteins of the invention that are capable of neutralizing or eliminating the toxic species can be gamma glutamyl transpeptidase,

manganese **superoxide dismutase**, or metallothionein.

SUMMARY:

BSUM(16)

In . . . of the invention comprises a mixture of polynucleotides selected from a polynucleotide encoding gamma glutamyl transpeptidase, a polynucleotide encoding manganese **superoxide dismutase** or a polynucleotide encoding metallothionein. Alternatively, the pharmaceutical composition of the invention can comprise a polynucleotide encoding gamma glutamyl transpeptidase, a polynucleotide encoding manganese **superoxide dismutase** or a polynucleotide encoding metallothionein.

SUMMARY:

BSUM(18)

Another . . . polynucleotide in such a composition of the invention can be a polynucleotide encoding gamma glutamyl transpeptidase, a polynucleotide encoding manganese **superoxide dismutase** or a polynucleotide encoding metallothionein. The pharmaceutically acceptable vehicle in such a composition of the invention can be a liposome,. . .

DRAWING DESC:

DRWD(4)

FIGS. 3A and 3B are schematic drawings of the construction of a manganese **superoxide dismutase** recombinant adenovirus vector (Ad-MnSOD). FIG. 3A illustrates the Wild-type Adenovirus type 5 (Ad5) genome showing the E1a, E1band E3 regions. . . the appropriate expression cassettes. FIG. 3B illustrates an expression cassette containing regulatory sequences and a recombinant DNA sequence encoding manganous **superoxide dismutase**.

DETDESC:

DETD(4)

The . . . wherein the protein is transiently expressed in the individual. The transgenes of the present invention encode protein(s), such as metallothionein, **superoxide dismutase** or gamma glutamyl transpeptidase, that scavenge a toxic free radical, superoxide anion and/or heavy metal cation.

DETDESC:

DETD(11)

Protection against superoxide radicals requires antioxidants, such as GSH, and the O.sub.2.sup.- -scavenging enzyme **superoxide dismutase** (SOD). SODs are metalloenzymes that are essential for dismutation of O.sub.2.sup.- to H.sub.2 O.sub.2 and O.sub.2. There are three forms. . .

DETDESC:

DETD(21)

Viruses . . . multiple copies of the gene of interest into every cell in a culture, thus providing high efficiency transfection in vivo. **Adenoviral vectors** provide one useful means for delivering genes in vivo because adenoviruses can efficiently infect nondividing cells and

can direct various. . . . Vector-mediated gene expression can be achieved in a vari[redacted]tissues by administration of a [redacted]ncentrated solution containin[redacted]desired **adenoviral vector**. Rosen[redacted] et al., Science 252: 431 (1991); Quantin et al., Proc. Natl. Acad. Sci. USA 89: 2581 (1992); Stratford-Perricaudet et. . .

DETDESC:

DETD(22)

When . . . Natl. Acad. Sci USA 84: 7413 (1987). For transfection of pulmonary epithelium, the method of the present invention preferably utilizes **adenoviral vectors**, lipofection with liposomes or ligand-DNA conjugates.

DETDESC:

DETD(31)

In . . . can be constructed so as to transfer and express, in respiratory epithelium, the DNA encoding either gamma glutamyl transpeptidase, manganese **superoxide dismutase**, metallothionein, a combination of DNA sequences encoding any two of these proteins, or a combination of DNA sequences encoding all. . .

DETDESC:

DETD(34)

A DNA sequence encoding the entire **superoxide dismutase**, preferably MnSOD, coding region is isolated or synthesized by methods well known to the art based on the MnSOD sequences. . .

DETDESC:

DETD(36)

DNA . . . 2 pseudogene 1; :b: ATCC 57152, 57153--bMT-IIA containing the human metallothionein 2 gene; :c: ATCC 20745--pYAS11 containing cDNA encoding human **superoxide dismutase** 1; :d: ATCC 20796--pYLUIGF2-14 containing DNA encoding human **superoxide dismutase** 1; :e: ATCC 39786--pSOD alpha 2 containing DNA encoding human **superoxide dismutase** 1; :f: ATCC 59946, 59947--phMnSOD4 containing DNA encoding human **superoxide dismutase** 2; :g: ATCC 61646, 61647 containing cDNA encoding human **superoxide dismutase** 1; :h: ATCC 86406--IB881 containing cDNA encoding human **superoxide dismutase** or (3) polymerase chain reaction amplification of the desired DNA sequences from the DNA libraries disclosed in the above references. . .

DETDESC:

DETD(41)

A second way to produce the recombinant **adenoviral vector** of the present invention is to coprecipitate a linearized plasmid containing the desired cDNA encoding MT, .gamma.-GTP or MnSOD with. . .

DETDESC:

DETD(42)

Recombinant adenovirus plaques containing the human gamma glutamyl transpeptidase, manganese **superoxide dismutase** and metallothionein protein cDNA (Ad-.gamma.GTP; Ad-MnSOD, and Ad-MT

respectively) are then identified by restriction cleavage, Southern analysis and/or No[redacted] analysis. . .

DETDESC:

DETD(43)

Each . . . cells. Any tissue of the human body can be targeted for the gene therapy of the present invention using the **adenoviral vectors** described above. These vectors can be introduced by intratracheal, intravenous, intraperitoneal, intramuscular, intrarectal, intravesicle, intraintestinal, intraoral, intraocular or intraarterial injections.

DETDESC:

DETD(57)

Immunohistochemical Detection of the Human Gamma Glutamyl Transpeptidase, Manganese **Superoxide Dismutase** and Metallothionein After In Vivo Infection

DETDESC:

DETD(58)

Human gamma glutamyl transpeptidase, manganese **superoxide dismutase** and metallothionein are evaluated in cytocentrifuge preparations of human lung epithelial lavage samples or lung biopsy samples taken 2 days,. . . or Ad-.gamma.-GTP. The alkaline phosphatase monoclonal anti-alkaline phosphatase method is used with antibodies specific for human gamma glutamyl transpeptidase, manganese **superoxide dismutase** and metallothionein antibody. Cordell et al., J. Histol. Cytochem. 32: 219 (1984).

DETDESC:

DETD(60)

The in vitro or in vivo expressed human gamma glutamyl transpeptidase, manganese **superoxide dismutase** and metallothionein are each tested for their functional activity.

DETDESC:

DETD(71)

Construction of the recombinant **adenoviral vector** Ad-MT and expression of recombinant MT from lung epithelium in vivo

DETDESC:

DETD(76)

Construction of the recombinant **adenoviral vector** Ad-MnSOD and expression of recombinant MnSOD from lung epithelium in vivo

DETDESC:

DETD(81)

Construction of the recombinant **adenoviral vector** Ad-.gamma.-GTP and expression of recombinant .gamma.-GTP from lung epithelium in vivo

CLAIMS:

CLMS(1)

What . . .
toxic species to provide a protection therefrom and (ii) is selected from a group consisting of gamma glutamyl transpeptidase, manganese **superoxide dismutase**, and metallothionein;
(B) a pharmaceutically acceptable vehicle for said polynucleotide wherein said vehicle is selected from a liposome and a replication-deficient. . .

CLAIMS:

CLMS(11)

11. The method of claim 1, wherein said protein is manganese **superoxide dismutase**.

CLAIMS:

CLMS(13)

13. . . . a mixture of polynucleotides selected from the group consisting of a polynucleotide encoding gamma glutamyl transpeptidase, a polynucleotide encoding manganese **superoxide dismutase** and a polynucleotide encoding metallothionein.

CLAIMS:

CLMS(15)

15. The method of claim 1, wherein said pharmaceutical composition comprises a polynucleotide encoding manganese **superoxide dismutase**.

CLAIMS:

CLMS(25)

25. . . .
with said toxic species to provide protection therefrom and (b) is selected from a group consisting gamma glutamyl transpeptidase, manganese **superoxide dismutase**, and metallothionein; and
(B) a pharmaceutically acceptable vehicle for said polynucleotide wherein said vehicle is selected from a liposome and. . .

=> d kwic,4

US PAT NO: 5,571,797 :IMAGE AVAILABLE: L3: 4 of 6

SUMMARY:

BSUM(13)

Preferably, . . . a vascular smooth muscle growth factor is platelet derived growth factor (PDGF); and 4) a free radical scavenger is manganese **superoxide dismutase** (MnSOD).

DETDESC:

DETD(45)

Preferably, . . . a vascular smooth muscle growth factor is platelet derived growth factor (PDGF); and 4) a free radical scavenger is manganese **superoxide dismutase** (MnSOD).

DETDESC:

DETD(48)

TNF may induce radioprotection through the production of manganese **superoxide dismutase** (MnSOD), which has been shown to be associated with radiation resistance in the T-cell line HUT-78 (Wong, et al., 1991).. . .

DETDESC:

DETD(124)

Plasmid . . . about 491 base pair fragment of the Egr-1 promoter operatively linked to an encoding region for the free-radical scavenger manganese **superoxide dismutase** (MnSOD). pE425-MnSOD was constructed from a plasmid nMnSOD #0664 (Genentech) (Wong, 1989) which contains MnSOD cDNA and pE425-CAT, which contains. . .

DETDESC:

DETD(206)

A . . . adeno-associated virus (AAV vectors), such as those described by U.S. Pat. No. 5,139,941, incorporated herein by reference; and, particularly, recombinant **adenoviral vectors**. Techniques for preparing replication-defective infective viruses are well known in the art, as exemplified by Ghosh-Choudhury & Graham (1987); McGrory. . .

=> d kwic,5

US PAT NO: 5,552,309 :IMAGE AVAILABLE: L3: 5 of 6

ABSTRACT:
A process for introducing an expression vehicle (e.g., plasmids, retroviral vectors, **adenoviral vectors**) into cells, which comprises contacting the cells with the expression vehicle and a polyol. The polyol may be a polyoxalkylene. . .

SUMMARY:

BSUM(3)

The . . . 83, pgs. 2007-2011 (1991)), retroviral vectors (Nabel, et al., 1990; Flugelman, et al., Circulation, Vol. 85, pgs. 1110-1117 (1992)) and **adenoviral vectors** (Guzman, et al., Circulation, Vol. 88, pgs. 2838-2848 (1993); Lemarchand, et al., Proc. Nat. Acad. Sci., Vol. 89, pgs. 6482-6486. . .

SUMMARY:

BSUM(4)

Gene delivery vehicles which may be employed include retroviral vectors and **adenoviral vectors**. Retroviral vectors may be employed for infecting dividing cells, while **adenoviral vectors** may be employed for infecting dividing and non-dividing cells. **Adenoviral vectors** have been used successfully for in vivo gene transfer of marker genes such as .beta.-galactosidase (Stratford-Perricaudet, et al., Hum. Gene. . .

SUMMARY:

BSUM(16)

Expression . . [redacted]or, such plasmid vector may be [redacted]ntained within an infectious viral [redacted]ctor particle, such as a retrovir[redacted]vector particle, an **adenoviral vector** particle, or an adeno-associated virus vector particle.

SUMMARY:

BSUM(17)

In . . . viral vector particle, sometimes hereinafter referred to as a "viral vector." The viral vector may be a retroviral vector, an **adenoviral vector**, an adeno-associated virus vector, or a Herpes Virus vector.

SUMMARY:

BSUM(18)

In one embodiment, the viral vector is an **adenoviral vector**.

SUMMARY:

BSUM(19)

The **adenoviral vector** which is employed may, in one embodiment, be an **adenoviral vector** which includes essentially the complete adenoviral genome (Shenk, et al., Curr. Top. Microbiol. Immunol., 111(3): 1-39 (1984)). Alternatively, the **adenoviral vector** may be a modified **adenoviral vector** in which at least a portion of the adenoviral genome has been deleted.

SUMMARY:

BSUM(20)

In one embodiment, the **adenoviral vector** comprises an adenoviral 5' ITR; an adenoviral 3' ITR; an adenoviral encapsidation signal; and at least one DNA sequence encoding. . .

SUMMARY:

BSUM(25)

This construct is then used to produce an **adenoviral vector**. Homologous recombination is effected with a modified or mutated adenovirus in which at least the majority of the E1 and. . . aids in enabling the plasmid vector and modified adenovirus to transfect the helper cells. Upon such homologous recombination, a recombinant **adenoviral vector** is formed that includes DNA sequences derived from the shuttle plasmid between the NotI site and the homologous recombination fragment,. . .

SUMMARY:

BSUM(28)

In one embodiment, the **adenoviral vector** comprises an adenoviral 5' ITR; an adenoviral 3' ITR; an adenoviral encapsidation signal; and at least one DNA sequence encoding. . .

SUMMARY:

BSUM(34)

The present invention is particularly applicable to the treatment of diseases of the bl[redacted]sel wall. For example, infect[redacted] **adenoviral vector** particles w[redacted] include at least one nucleic aci[redacted]equence encoding therapeutic agent for treating a disease of the blood vessel. . . such re-implanted cells express the agent for treating a disease of the blood vessel wall in vivo. For example, the **adenoviral vector** particle may include an antisense c-myb oligonucleotide, which is employed for inhibiting intimal arterial smooth muscle cell accumulation. Other diseases. . .

SUMMARY:

BSUM(35)

Alternatively, the infectious adenoviral particles may be administered in vivo in combination with the polyol, to a host, whereby the infectious **adenoviral vector** particles will infect cells in vivo in a host, thereby providing for in vivo expression of the therapeutic agent in. . . viral particles are administered in an amount effective to produce a therapeutic effect in a host. In one embodiment, the **adenoviral vector** particles may be administered in an amount of from about 1 to about 10.sup.14 plaque forming units (pfu), preferably from. . . from about 10.sup.6 to about 10.sup.10 pfu. The host may be a human or non-human host. The exact dosage of **adenoviral vector** particles which may be administered is dependent upon the age, sex, and weight of the patient, the therapeutic agent which. . .

SUMMARY:

BSUM(36)

The infectious **adenoviral vector** particles and the polyol may be administered systemically, such as, for example, by intravenous or intraperitoneal administration, as well as. . .

SUMMARY:

BSUM(37)

The **adenoviral vector** particles and the polyol may be administered in combination with a physiologically acceptable pharmaceutical carrier. Such pharmaceutical carriers include, but. . .

SUMMARY:

BSUM(38)

DNA sequences encoding therapeutic agents may be placed into the **adenoviral vector** include, but are not limited to, DNA sequences encoding tumor necrosis factor (TNF) genes, such as TNF-.alpha.; genes encoding interferons. . . of hepatitis B or hepatitis non-A non-B virus; antisense c-myb oligonucleotides; and antioxidants such as, but not limited to, manganese **superoxide dismutase** (Mn-SOD), catalase, copper-zinc-**superoxide dismutase** (CuZn-SOD), extracellular **superoxide dismutase** (EC-SOD), and glutathione reductase; tissue plasminogen activator (tPA); urinary plasminogen activator (urokinase); hirudin; nitric oxide snythesase; vasoactive peptides; and angiogenic. . .

DRAWING DESC:

DRWD(4)

FIG. 2 is a schematic of the construction of an **adenoviral vector** including an ITR, an encapsidation signal, a Rous Sarcoma

Virus promoter, and an adenoviral tripartite leader (TPL) sequence;

DETDESC:

DETD(5)

The **adenoviral vector** used in this example was a replication deficient E1a/E1b.sup.-, E3.sup.- deletion mutant expressing a nuclear-targeted .beta.-galactosidase gene under the control. . .

DETDESC:

DETD(13)

The recombinant, replication-deficient **adenoviral vector** Av1Lac Z4, which expresses a nuclear-targetable B-galactosidase enzyme, was constructed in two steps. First, a transcriptional unit consisting of DNA. . .

DETDESC:

DETD(14)

The . . . was isolated by agarose gel electrophoresis and purified. The ClaI fragment was used as the backbone for all first generation **adenoviral vectors**, and the vectors derived from it are known as Av1.

DETDESC:

DETD(18)

Adenoviral vector morphology and integrity were evaluated by high-resolution scanning electron microscopy. Briefly, bovine aortic smooth muscle cells were plated on silicon. . .

CLAIMS:

CLMS(5)

5. The process of claim 1 wherein said viral particle is an **adenoviral vector** particle.

CLAIMS:

CLMS(13)

13. The composition of claim 9 wherein said viral vector is an **adenoviral vector** particle.

=> d kwic,6

US PAT NO: 5,496,731 :IMAGE AVAILABLE: L3: 6 of 6

SUMMARY:

BSUM(73)

In . . . may be any host cell-compatible vector. The vector is preferably selected from the group consisting of a retroviral vector, an **adenoviral vector** and a herpesviral vector.

DETDESC:

DETD(135)

In . . . al., [redacted]iotechniques, 6:682-690). Prot[redacted]s such as erythrocyte anion [redacted]sporter (Newton, A. C. and Hueste[redacted]W. H., Biochemistry, 1988, 27:4655-4659), **superoxide dismutase** and catalase (Tanswell, A. K. et al., 1990, Biochmica et Biophysica Acta, 1044:269-274), and UV-DNA repair enzyme (Ceccoll, J. et. . .

CLAIMS:

CLMS(5)

5. . . . vector according to claim 3 wherein said viral vector is selected from a group consisting of a retroviral vector, an **adenoviral vector**, and a herpesviral vector.

=> d fro,1-6

US PAT NO: 5,670,488 :IMAGE AVAILABLE: L3: 1 of 6
DATE ISSUED: Sep. 23, 1997
TITLE: Adenovirus vector for gene therapy
INVENTOR: Richard J. Gregory, Carlsbad, CA
Donna Armentano, Watertown, MA
Larry A. Couture, Framingham, MA
Alan E. Smith, Wellesley, MA
ASSIGNEE: Genzyme Corporation, Framingham, MA (U.S. corp.)
APPL-NO: 08/136,742
DATE FILED: Oct. 13, 1993
REL-US-DATA: Continuation-in-part of Ser. No. 985,478, Dec. 3, 1992, abandoned.
INT-CL: :6: A61K 48/00; C12N 15/00
US-CL-ISSUED: 514/44; 424/93.2; 435/320.1; 935/62
US-CL-CURRENT: 514/44; 424/93.2; 435/320.1; 935/62
SEARCH-FLD: 435/320.1; 514/44; 424/93.2; 935/62
REF-CITED:

U.S. PATENT DOCUMENTS

4,920,209	4/1990	Davis

FOREIGN PATENT DOCUMENTS

0 185 573	6/1986	European Patent Office
0 446 017	9/1990	European Patent Office
WO 91/02796	8/1990	World Intellectual Property Organization
WO 93/12240	12/1992	World Intellectual Property Organization
WO 93/12756	12/1992	World Intellectual Property Organization
WO 91/10734	12/1992	World Intellectual Property Organization
93 19191	9/1993	World Intellectual Property Organization

OTHER PUBLICATIONS

Zabner, J. et al. (1993) "Adenovirus-Mediated Gene Transfer Transiently Corrects the Chloride Transport Defect in Nasal Epithelia of Patients with Cystic Fibrosis" Cell 75:207-216.
Rosenfeld, M.A. et al. (1992) "In Vivo Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to the Airway Epithelium" Cell 68: 143-155.
Sassone-Corsi, P. et al. (1983) "Far upstream sequences are required for efficient transcription from the adenovirus-2 E1A transcription unit" Nucleic Acid Research 11:8735-8745.
Yoshimura, K. et al. (1993) "Adenovirus-mediated Augmentation of Cell Transfection with Unmodified Plasmid Vectors" J. Biol. Chem. 268(4):2300-2303.

Engelhardt, J.F. et al. (1993) "Direct Gene Transfer of Human CFTR into Human Bronchial [redacted]ia of Xenografts with E1-delet[redacted]Adenovirus" Nat. Gen. 4:27-3[redacted]
Flotte, T.R. et al. (1993) "Expression of the Cystic Fibrosis Transmembrane Conductance Regulator from a Novel Adeno-associated Virus Promoter" J. Biol. Chem. 268(5):3781-3790.
Johnson, L.G. et al. (1992) "Efficiency of Gene Transfer for Restoration of Normal Airway Epithelial Function in Cystic Fibrosis" Nat. Gen. 2:21-25.
Welsh, M.J. and Smith, A.E. (1993) "Molecular Mechanisms of CFTR Chloride Channel Dysfunction in Cystic Fibrosis" Cell 73:1251-1254.
Hyde, S.C. et al. (1993) "Correction of the Ion Transport Defect in Cystic Fibrosis Transgenic Mice by Gene Therapy" Nature 362:250-255.
Smith, A.E. (1992) "Emerging Therapies for Cystic Fibrosis" Section V-Topics in Biology in Ann. Rep. Med. Chem. 27:235-243.
Yoshimura, K. et al. (1992) "Expression of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene in the Mouse Lung after in Vivo Intratracheal Plasmid-Mediated Gene Transfer" Nucleic Acids Res. 20:(12):3233-3240.
Rosenfeld, M.A. et al. (1991) "Adenovirus-Mediated Transfer of a Recombinant .alpha.-1-Antitrypsin Gene to the Lung Epithelium in Vivo" Science 252:431-434.
Rosenfeld, M.A. et al. (1991) "In Vivo Transfer of the Human Cystic Fibrosis Gene to the Respiratory Epithelium" Clin. Res. 39(2):311A.
Anderson, M.P. et al. (1991) "Generation of cAMP-Activated Chloride Currents by Expression of CFTR" Science 251:679-682.
Kartner, N. et al. (1991) "Expression of the Cystic Fibrosis Gene in Non-Epithelial Invertebrate Cells Produces a Regulated Anion Conductance" Cell 64:681-691.
Anderson, M.P. et al. (1991) "Demonstration That CFTR Is a Chloride Channel by Alteration of Its Anion Selectivity" Science 253:202-205.
Tabcharani, J.A. et al. (1991) "Phosphorylation-Regulated C1-Channel in CHO Cells Stabley Expressing the Cystic Fibrosis Gene" Nature 352:628-631.
Rich, D.P. et al. (1991) "Effect of Deleting the R Domain on CFTR-Generated Chloride Channels" Science 253:205-207.
Berger, H.A. et al. (1991) "Identification and Regulation of the Cystic Fibrosis Transmembrane Conductance Regulator-Generated Chloride Channel" J. Clin. Invest. 88:1422-1431.
Drumm, M.L. et al. (1990) "Correction of the Cystic Fibrosis Defect In Vitro By Retrovirus-Mediated Gene Transfer" Cell 1227-1233.
Gregory, R.J. et al. (1990) "Expression and Characterization of the Cystic Fibrosis Transmembrane Conductance Regulator" Nature 347:382-386.
Rich, D.P. et al. (1990) "Expression of the Cystic Fibrosis Transmembrane Conductance Regulator Corrects Defective Chloride Channel Regulation in Cystic Fibrosis Airway Epithelial Cells" Nature 347:358-363.
Huang, M.T.F. et al. (1990) "Intervening Sequences Increase Efficiency of RNA 3'Processing and Accumulation of Cytoplasmic RNA" Nucleic Acids Res. 18(4):937-947.
Riordan, J.R. et al. (1989) "Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA" Science 245:1066-1073.
Rommens, J.H. et al. (1989) "Identification of the Cystic Fibrosis Gene: Chromosome Walking and Jumping" Science 245: 1059-1065.
Kerem, B.S. et al. (1989) "Identification of the Cystic Fibrosis Gene: Genetic Analysis" Science 245:1073-1080.
Berker (1988) Biotechniques 6, 616-627.

ART-UNIT: 189
PRIM-EXMR: Deborah Crouch
LEGAL-REP: Brumbaugh, Graves Donohue & Raymond

ABSTRACT:
Gene Therapy vectors, which are especially useful for cystic fibrosis, and methods for using the vectors are disclosed.

19 Claims, 67 Drawing Figures

US PAT NO: 5,641,662 :IMAGE AVAILABLE: L3: 2 of 6
DATE ISSUED: Jun. 24, 1997
TITLE: Transfection of lung via aerosolized transgene delivery
INVENTOR: Robert James Debs, Mill Valley, CA
Ning Zhu, El Cerrito, CA
ASSIGNEE: The Regents of the University of California, Oakland, CA (U.S. corp.)
APPL-NO: 08/029,022
DATE FILED: Mar. 10, 1993
REL-US-DATA: Continuation-in-part of Ser. No. 972,135, Nov. 5, 1992, which is a continuation-in-part of Ser. No. 809,291, Dec. 17, 1991, abandoned.
INT-CL: :6: C12N 15/64; C12N 15/87; A61K 48/00; A61K 9/127
US-CL-ISSUED: 435/172.1, 172.3, 320.1; 424/450; 514/44; 128/200.14, 200.24; 536/24.1; 436/71
US-CL-CURRENT: 435/172.1; 128/200.14, 200.24; 424/450; 435/172.3, 320.1; 436/71; 514/44; 536/24.1
SEARCH-FLD: 514/44; 424/450; 435/172.1, 172.3, 320.1; 935/62, 54, 55; 128/200.14, 200.24; 536/24.1; 436/71

REF-CITED:

U.S. PATENT DOCUMENTS

3,826,255	7/1974	Havstad et al.	128/194
4,046,146	9/1977	Rosskamp et al.	128/266
4,253,468	3/1981	Lehmbeck	128/726
4,268,460	5/1981	Boiarski et al.	261/1
4,394,448	7/1983	Szoka et al.	435/172
4,510,929	4/1985	Bordoni et al.	128/200.14
4,649,911	3/1987	Knight et al.	128/200.21
4,804,678	2/1989	Augstein et al.	514/456
4,946,787	8/1990	Eppstein et al.	435/240.2
5,240,842	8/1993	Mets	435/172.3
5,240,846	8/1993	Collins et al.	435/240.1
5,264,618	11/1993	Felgnet et al.	560/224

FOREIGN PATENT DOCUMENTS

0446017A1	9/1991	European Patent Office
WO90/11092	10/1990	World Intellectual Property Organization
WO91/02796	3/1991	World Intellectual Property Organization
WO91/06309	5/1991	World Intellectual Property Organization
WO91/17773	11/1991	World Intellectual Property Organization

OTHER PUBLICATIONS

Brigham et al., Am. J. Med. Sci., vol. 298 (1989) pp. 278-281.
Canonico et al. (1991) Expression of a CMV promoter driven human .alpha.1-antitrypsin gene in cultured lung endothelial cells and in the lungs of rabbits, Clinica Research, 39: 219(A).
Debs et al. (1990) Biodistribution, tissue reaction and lung retention of pentamidine aerosolized as three different salts, Am. Rev. Respir. Dis., 142: 1164-1167.
Felgner et al. (1987) Lipofection: A highly efficient, Lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. USA, 84: 7413-7417.
Hubbard et al. (1989) Fate of aerosolized recombinant DNA-produced .alpha.1-antitrypsin: Use of the epithelial surface of the lower respiratory tract to administer protein of therapeutic importance. Proc. Natl. Acad. Sci. USA, 86:680-684.
Hug. et al. (1991) Liposomes for the transformation of eukaryotic cells. Biochem. et Biophysica Acta, 1097: 1-17.
Malone et al. (1989) Cationic liposome-mediated RNA transfection., Proc.

Natl. Acad. Sci. USA, 86: 6077-6081.
Mannino et al. (19[redacted]osome mediated gene transfer.' techniques, 6: 682-690.
Rosenfeld et al. (1991) Adenovirus-mediated transfer of a recombinant .alpha.1-antitrypsin gene to the lung epithelium in vivo. Science, 252: 431-434.
Brigham et al. (1989) Expression of a prokaryotic gene in cultured lung endothelial cells after lipofection with a plasmid vector. Am. J. Respir. Cell. Mol. Biol. 1: 95: 100.
Debs et al. (1987) Amer. Rev. Respir. Dis,. 135: 731-737.
Debs et al. (1987) Antimicrob. Agents Chemother., 31: 37-42.
Debs et al. (1988) J. Immunol., 140: 3482-3488.
Gregoriadis (1985) Trends in Biotechnology, 3(9): 235-241.
Hazinski et al. (1991) Am. J. Respir. Cell. Mol. Biol. 4: 206-209.
Holden (1991) Science, 253: 964-965.
Huang et al. (1990) Molecular and Cellular Biology, 10: 1805-1810.
Leoung et al. (1990) N. Eng. J. Med., 323: 769-775.
Montgomery et al. (1989) Chest, 95: 747-751.
Montgomery et al. (1987) Lancet 11: 480-483.
Nabel et al. (1990) Science, 249: 1285-1288.
Straubinger et al. (1993) Meth. Enzymol., 101: 512-527.
Wolff et al. (1990) Science 247: 1465-1468.
Debs et al. (1990) Regulation of gene expression in vivo by liposome-mediated delivery of a purified transcription factor, J. Biol. Chem., 265: 10189.
Knowles et al. (1990) A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N. Engl. J. Med., 322: 1189-1194.
Mercer, (1981) Production of therapeutic aerosols. Chest, 80(6): 813.
Mercer et al. (1968) Operating characteristics of some compressed-air nebulizers., Am. Ind. Hyg. Assoc. J., 29: 66-78.
Rose et al. (1991) A new cationic liposome reagent mediating nearly quantitative transfection of animal cells. Biotechniques, 10: 520-525.
ART-UNIT: 184
PRIM-EXMR: Charles C. P. Rories
LEGAL-REP: Townsend and Townsend and Crew

ABSTRACT:
Methods and compositions for producing a mammal capable of expressing an exogenously supplied gene in cells of the airway are disclosed. Lipid carrier-nucleic acid complexes are prepared then delivered via aerosol to the lung airway. The invention provides a direct method for transforming pulmonary cells as a means for treating disorders of the lung as for providing a means for delivering substances systematically following expression in the lung.
15 Claims, 45 Drawing Figures

US PAT NO: 5,599,712 :IMAGE AVAILABLE: L3: 3 of 6
DATE ISSUED: Feb. 4, 1997
TITLE: Protection from ionizing irradiation or chemotherapeutic drug damage by in vivo gene therapy
INVENTOR: Joel S. Greenberger, Sewickley, PA
ASSIGNEE: University of Pittsburgh, Pittsburgh, PA (U.S. corp.)
APPL-NO: 08/136,079
DATE FILED: Oct. 15, 1993
INT-CL: :6: A61K 48/00; C12N 15/00
US-CL-ISSUED: 435/267, 320.1; 514/44; 424/93.21, 93.2
US-CL-CURRENT: 435/267; 424/93.2, 93.21; 435/320.1; 514/44
SEARCH-FLD: 514/44, 2; 435/172.3, 320.1, 172.1, 172.2, 172.3, 172.4; 424/94.1, 94.3, 94.4, 93.1, 93.21
REF-CITED:

OTHER PUBLICATIONS

Xiang, K., "Multiple Taq I RFLPs at the Human Manganese Superoxide

Dismutase (SOD2) locus on Chromosome 6", Nucleic Acids Research, vol. 15, No. 18 (1987).
Hyland, V. J. et al., "A 5' Flanking Region of the Metallothionein, MT2A, Gene Identifies Two Moderately Frequent RFLPs", Nucleic Acids Research, vol. 15, No. 3 (1987).
Karin, M. et al., "Human Metallothionein Genes-Primary Structure of the Metallothionein-II Gene and a Related Processed Gene", Nature, vol. 299 (Oct. 28, 1982).
Sherman, L. et al., "Nucleotide Sequence and Expression of Human Chromosome 21-encoded Superoxide Dismutase mRNA", Proc. Natl. Acad. Sci. USA, vol. 80, pp. 5465-5469 (Sep. 1983).
Richards, R. I. et al., "Structural and Functional Analysis of the Human Metallothionein-I.sub.A Gene: Differential Induction by Metal Ions and Glucocorticoids", Cell, vol. 37, pp. 263-272 (May 1984).
Lieman-Hurwitz, J. et al., "Human Cytoplasmic Superoxide Dismutase cDNA Clone: A Probe for Studying the Molecular Biology of Down Syndrome", Proc. Natl. Acad. Sci. USA, vol. 79, pp. 2808-2811 (May 1982).
Cai, D. W. et al., "Stable Expression of the Wild-Type p53 Gene in Human Lung Cancer Cells After Retrovirus-Mediated Gene Transfer", Proceedings of the American Association of Cancer Research, vol. 34, pp. 505, 3011 (Mar. 1993).
McCormick, M. L. et al., "Superoxide Dismutase and Catalase Levels During Estrogen-Induced Renal Tumorigenesis, in Renal Tumors and their Autonomous Variants in the Syrian Hamster", Carcinogenesis, vol. 12, No. 6, pp. 977-983 (1991).
Engelhardt, J. et al., "In Vivo Retroviral Gene Transfer into Human Bronchial Epithelia of Xenografts", The American Society for Clinical Investigation, Inc., vol. 90, pp. 2598-2609 (Dec. 1992).
Oberley, L. W. et al., "Transfection of Manganese Superoxide Dismutase cDNA into Cultured Tumor Cells," Proc. Amer. Assoc. for Canc. Res., Abstract 98 (1993).
Yang, Y., et al. "An Approach for Treating the Hepatobiliary Disease of Cystic Fibrosis by Somatic Gene Transfer", Proc. Natl. Acad. Sci. USA, vol. 90, pp. 4601-4605 (May 1993).
Rosenfeld, M. A. et al., "Adenovirus-Mediated Transfer of a Recombinant .alpha.I-Antitrypsin Gene to the Lung Epithelium in Vivo", Reports, pp. 431-434 (Apr. 19, 1991).
Dunn, M. A. et al., "Minireview--Metallothionein (42525A)", Proceedings of the Society for Experimental Biology and Medicine 185, pp. 107-119 (1987).
Lohrer, H. et al., "Overexpression of Metallothionein in CHO Cells and its Effect on Cell Killing by Ionizing Radiation and Alkylating Agents", Carcinogenesis, vol. 10, No. 12, pp. 2279-2284 (1989).
Holland, C. et al., "Enhancer Sequences of a Retroviral Vector Determine Expression of a Gene in Multipotent Hematopoietic Progenitors and Committed Erythroid Cells", Proc. Natl. Acad. Sci. USA, vol. 84, pp. 8662-8666 (Dec. 1987).
Roth, J. et al., "p53 Regulates the Transcription of Human Cytokeratin .beta. Gene in Human Lung Cancer Cell Lines", Proceedings of The American Association for Cancer Research, vol. 34, p. 509 (Mar. 1993).
Petkau, A., "Scientific Basis for the Clinical Use of Superoxide Dismutase", Cancer Treatment Reviews 13, pp. 17-44 (1986).
Fujiwara, T. et al., "Retroviral-Mediated Transduction of p53 Gene Regulates TGF-.beta. Gene Expression and Secretion in a Human Glioblastoma Cell Line", Proceedings of the American Association for Cancer Research, vol. 34, pp. 449, 2680 (Mar. 1993).
Georges, R. N. et al., "In-Vivo Retroviral Transduction of Antisense K-ras Suppresses Tumor Growth in an Orthotopic Lung Cancer Model", Proceedings of the American Association for Cancer Research, vol. 34, p. 336 (Mar. 1993).
Shiraishi, N. et al., "Elevation in Metallothionein Messenger RNA in Rat Tissues After Exposure to X-Irradiation", Toxicology and Applied Pharmacology 98, pp. 501-506 (1989).
Flotte, T. et al., "Gene Expression from Adeno-Associated Virus Vectors in Airway Epithelial Cells", Am. J. Respir. Cell Molec. Biol, 7:349

(1992).
Anklesaria, P. et al., "Engraftment of a Clonal Bone Marrow Stromal Cell Line in vivo Stimulates Hematopoietic Recovery from Total Body Irradiation", Proc. Natl. Acad. Sci. USA, vol. 84, pp. 7681-7685, (Nov. 1987).
Armstrong, J. G. et al., "Three Dimensional Conformal Radiation Therapy May Improve the Therapeutic Ratio of High Dose Radiation Therapy for Lung Cancer", Int. J. Radiation Oncology Biol. Phys., vol. 00, pp. 001-005 (1993).
Georges, R. N. et al., "Prevention of Orthotopic Human Lung Cancer Growth by Intratracheal Instillation of a Retroviral Antisense K-ras Construct", Cancer Research 53, pp. 1743-1746 (Apr. 15, 1993).
Stribling, R., "Aerosol Gene Delivery in vivo", Proc. Natl. Acad. Sci. USA, vol. 89, pp. 11277-11281, (Dec. 1992).
Ferkol, T. et al., "Regulation of the Phosphoenolpyruvate Carboxykinase/human Factor IX Gene Introduced into the Livers of Adult Rats by Receptor-Mediated Gene Transfer", Methodology, vol. 7, pp. 1081-1091, (Aug. 1993).
Rosenfeld, M. et al., "In Vivo Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene", Cell, vol. 68 (Jan. 10, 1992).
Mulligan, R., "The Basic Science of Gene Therapy", Science, vol. 260, pp. 926-932 (May 14, 1993).
Marshall, Eliot. "Gene Therapy's Growing Pains", Science 269: 1050-55 (1994).
Ledley, F D. "Clinical considerations in the design of protocols for somatic gene therapy," Human Gene Therapy 2: 77-83 (1991).
Ledley, F D. "Non-viral gene therapy," Current Opinion in Biotechnology 5: 626-636 (1994).
Lohrer, H et. al. "Overexpression of metallothionein in CHO cells and its effect on cell killing by ionizing radiation and alkylating agents," Carcinogenesis 10(12):2279-84 (1989).
Matsubara, J. et. al. "A New Perspective of Radiation Protection by Metallothionein Induction," Pharmac. Ther. 39: 331-333 (1988).
Alton, E W et. al. "Non-invasive liposome mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice", Nature Genetics 5: 135-42 (1993).
Hockenberry, D M et. al. "Bel-2 functions in an antioxidant pathway to prevent apoptosis," Cell 75: 241-251 (1993).
Jaffe, H A et. al. "Adenovirus-mediated in vivo gene transfer and expression in normal rat liver," Nature Genetics 1: 372-378 (1992).
Jolly, D. "Viral vector systems for gene therapy," Cancer Gene Therapy 1(1): 51-64 (1994).
Mulligan, R C. "The basic science of gene therapy," Science 260: 926-932 (1993).
Petkau, A. "Scientific basis for the clinical use of superoxide dismutase," Cancer Treatment Reviews 13: 17-44 (1986).
Sorrentino, B P et. al. "Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR-I", Science 257: 99-103 (1992).
Wu, G Y et. al. "Receptor-mediated gene delivery and expression in vivo," J. Biol. Chem. 263: 14621-14624 (1988).

ART-UNIT: 184
PRIM-EXMR: Jacqueline M. Stone
ASST-EXMR: Andrew Milne
LEGAL-REP: Foley & Lardner

ABSTRACT:
A method of protecting a subject against an agent that elicits production of toxic free radicals, superoxide anions, or heavy metal cations in the subject consisting of the in vivo administration to the subject of a polynucleotide encoding a protein that is transiently expressed in said subject. The transiently expressed protein is capable of neutralizing or eliminating the toxic free radicals, superoxide anions or heavy metal cations that are elicited by the agent. This method is particularly

useful in protecting cancer patients against the damaging effects of ionizing radiation [redacted] emotherapeutic drugs.
25 [redacted]ms, 8 Drawing Figures

US PAT NO: 5,571,797 :IMAGE AVAILABLE: L3: 4 of 6
DATE ISSUED: Nov. 5, 1996
TITLE: Method of inducing gene expression by ionizing radiation
INVENTOR: Tsuneya Ohno, Boston, MA
Ralph R. Weichselbaum, Chicago, IL
Donald W. Kufe, Wellesley, MA
ASSIGNEE: Arch Development Corporation, Chicago, IL (U.S. corp.)
APPL-NO: 08/241,863
DATE FILED: May 11, 1994
INT-CL: :6: A61K 48/00; A61K 51/00
US-CL-ISSUED: 514/44; 424/1.11, 1.49, 1.61, 1.65, 1.69, 450, 93.2, 93.21; 435/172.3, 320.1, 69.1, 69.5; 536/24.1; 935/6, 34, 59, 62
US-CL-CURRENT: 514/44; 424/1.11, 1.49, 1.61, 1.65, 1.69, 93.2, 93.21, 450; 435/69.1, 69.5, 172.3, 320.1; 536/24.1; 935/6, 34, 59, 62
SEARCH-FLD: 424/1.11, 1.29, 1.37, 1.49, 1.57, 450, 93.2, 93.21; 435/172.3, 320.1, 69.1, 69.5; 514/44; 536/23.1, 23.2, 23.5, 23.51, 23.52, 24.1, 23.7; 935/36, 62, 6, 34, 59
REF-CITED:

U.S. PATENT DOCUMENTS

5,128,126	7/1992	Boniver	424/85.5

FOREIGN PATENT DOCUMENTS

WO94/06916	3/1994	World Intellectual Property Organization

OTHER PUBLICATIONS

Weichselbaum et al (1992) Int J Radiation Oncology Biol Phys 24: 565-567.
Reuland et al (1991) Nucl Med Biol 18: 121-125.
Nedwin et al (1985) Nucleic Acids Research 13: 6361-6373.
Hallahan et al (1989) Proc Natl Acad Sci USA 86: 10104-10107.
Datta et al., "Ionizing radiation activates transcription of the EGR1 gene via CarG elements," Proc. Natl. Acad. Sci. USA, 89(21) :10149-10153, Nov., 1992.
Datta et al., "Reactive oxygen intermediates target CC(A/T) .sub.6 GG sequences to mediate activation of the early growth response 1 transcription factor gene by ionizing radiation," Proc. Natl. Acad. Sci. USA, 90(6) :2419-2422, Mar., 1993.
Gubits et al., "Expression of Immediate Early Genes After Treatment of Human Astrocytoma cells with Radiation and Taxol,"Int. J. Radiation Oncology Biol. Phys., 27(3) :637-642, Oct., 1993.
Luna et al., "Photodynamic Therapy Mediated Induction of Early Response Genes," Cancer Research, 54(5) :1374-1380, Mar., 1994.
Weichselbaum et al., "Radiation Induction of Immediate early Genes: Effectors of the Radiation-Stress Response," Int. J. Radiation Oncology Biol. Phys., 30(1) :229-234, Aug. 1994.
International Search Report dated Dec. 8, 1995.
K. Alexandropoulos, et al., "v-Fps-responsiveness in the Egr-1 Promoter is Mediated by Serum Response Elements", Nucleic Acids Research, 20(9): 2355-2359, 1992.
R. Attar, et al., "Expression Cloning of a Novel Zinc Finger Protein That Binds to the c-fos Serum Response Element", Molecular and Cellular Biology, 12 (5): 2432-2443, 1992.
D. Boothman, et al., "Identification and Characterization of X-Ray-induced Proteins in Human Cells", Cancer Research, 49: 2871-2878, 1989.
M. Brach, et al., "Ionizing Radiation Induces Expression and Binding Activity of the Nuclear Factor .kappa.B", The American Society for Clinical Investigation, Inc., 88: 691-695, 1991.
B. Christy, et al., "DNA Binding Site of the Growth Factor-Inducible

Protein Zif268", Proc. Natl. Acad. Sci, USA, 86: 8737-8741, 1989.
S. Dalton, et al., "[illegible]cterization of SAP-1, a Prote ecruited by Serum Response F[illegible]r to the c-fos Serum Response El t", Cell, 68: 597-612, 1992.
M. Gessler, et al., "Homozygous Deletion in Wilms Tumours of a Zinc-Finger Gene Identified by Chromosome Jumping", Nature, 343: 774-778, 1990.
D. Hallahan, et al., "Protein Kinase C Mediates X-ray Inducibility of Nuclear Signal Transducers EGR1 and JUN", Proc. Natl. Acad. Sci. USA, 88: 2156-2160, 1991.
D. Hallahan, et al., "Tumor Necrosis Factor Gene Expression is Mediated by Protein Kinase C Following Activation by Ionizing Radiation", Cancer Research, 51: 4565-4569, 1991.
M. Lambert, et al., "X-ray-Induced Changes in Gene Expression in Normal and Oncogene-Transformed Rat Cell Lines", Journal of the National Cancer Institute, 80(18): 1492-1497, 1988.
S. Qureshi, et al., "v-Src Activates Mitogen-Responsive Transcription Factor Egr-1 via Serum Response Elements", The Journal of Biological Chemistry, 266(17): 10802-10806, 1991.
S. Qureshi, et al., "v-Src Activates Both Protein Kinase C-Dependent and Independent Signaling Pathways in Murine Fibroblasts", Oncogene, 6: 995-999, 1991.
M. Sherman, et al., "Ionizing Radiation Regulates Expression of the c-jun Protooncogene", Proc. Natl. Acad. Sci. USA, 87: 5663-5666, 1990.
M. Sherman, et al., "Regulation of Tumor Necrosis Factor Gene Expression by Ionizing Radiation in Human Myeloid Leukemia Cells and Peripheral Blood Monocytes", The American Society for Clinical Investigation, Inc., 87: 1794-1797, 1991.
V. Sukhatme, et al., "A Zinc Finger-Encoding Gene Coregulated with c-fos During GFrowth and Differentiation, and After Cellular Depolarization", Cell, 53: 37-43, 1988.
R. Weichselbaum et al., "X-Ray Sensitivity of Fifty-three Human Diploid Fibroblast Cell Strains From Patients with Characterized Genetic Disorders", Cancer Research, 40: 920-925, 1980.
R. Weichselbaum, et al., "Radiation-Resistant and Repair-proficient Human Tumor Cells May Be Associated with Radiotherapy Failure in Head-and Neck-Cancer Patients", Proc. Natl. Acad, Sci, USA, 83: 2684-2688, 1986.
R. Weichselbaum, et al., "In Vitro Radiobiological Parameters of Human Sarcoma Cell Lines", Int. J. Radiation Oncology Biol. Phys., 15: 937-942, 1988.
L. Witte, et al., "Effects of Irradiation on the Release of Growth Factors from Cultured Bovine, Porcine, and Human Endothelial Cells", Cancer Research, 49: 5066-5072, 1989.

ART-UNIT: 184
PRIM-EXMR: Bruce R. Campell
LEGAL-REP: Arnold White & Durkee

ABSTRACT:
The present invention provides a method for delivering ionizing radiation to specific tissues, resulting in the activation of a DNA molecule comprising a radiation responsive enhancer-promoter operatively linked to an encoding region that encodes at least one polypeptide. The radiation source may be will generally be in the form of a radionuclide, capable of gamma or beta emissions. Processes for regulating polypeptide expression and inhibiting tumor growth using such DNA molecules are also provided.
16 Claims, 3 Drawing Figures

US PAT NO: 5,552,309 :IMAGE AVAILABLE: L3: 5 of 6
DATE ISSUED: Sep. 3, 1996
TITLE: Use of polyols for improving the introduction of genetic material into cells
INVENTOR: Keith L. March, Carmel, IN
ASSIGNEE: Indiana University Foundation, Bloomington, IN (U.S. corp.)

APPL-NO: 08/315,974
DATE FILED: Sep[redacted]994
INT-CL: :6: [redacted]63/00; C12N 5/00; C12N 15/00
US-CL-ISSUED: 435/172.3, 235.1, 240.2, 320.1; 514/44; 424/93.1, 93.2, 426; 935/57
US-CL-CURRENT: 435/172.3; 424/93.1, 93.2, 426; 435/235.1, 320.1; 514/44; 935/57
SEARCH-FLD: 424/93.1, 93.2, 426; 435/172.3, 320.1, 240.2; 514/44; 935/57
REF-CITED:

U.S. PATENT DOCUMENTS

5,118,512	6/1992	O'Leary et al.	424/549
5,298,222	3/1994	O'Leary et al.	422/28

OTHER PUBLICATIONS

Technical Data on Pluronic Polyol Gels, BASF Wyandotte Corporation, Parsippany, N.J.
Material Safety Data Sheet, Pluronic F127 NF (Poloxamer NF), BASF Corporation Chemicals Division, Parsippany, N.J.
Johnston, et al., Journal of Parenteral Science and Technology, vol. 48, No. 6, pp. 279-286 (Nov.-Dec. 1989).
Fults, et al., Journal of Parenteral Science and Technology, vol. 44, No. 2, pp. 58-65 (Mar.-Apr. 1990).
Schmolka, JAOCS, vol. 68, No. 3, pp. 206-209 (Mar. 1991).
Langer, et al., J. Cell. Biochem., vol. 45, pp. 340-345 (1991).
Johnston, et al., Pharmaceutical Research, vol. 9, No. 3 pp. 425-434 (1992).
March, et al., Cardio Intervention, pp. 11-26 (1992).
Pec, et al., Journal of Pharmaceutical Sciences, vol. 81, No. 7, pp. 626-630 (Jul. 1992).
Simons, et al., Nature, vol. 359, pp. 67-70 (Sep. 3, 1992).
Gunzman, et al., Circulation, vol. 88, No. 4, Part 2, pp. 1-80 (Oct. 1993).
Trapnell, Adv. Drug Del. Rev. vol. 12, pp. 185-199 (1993).
Smith, et al., Nature Genetics, vol. 5, pp. 397-401 (Dec. 1993).
Yei, et al., Human Gene Therapy, vol. 5, pp. 731-744 (1994).

ART-UNIT: 184
PRIM-EXMR: Bruce R. Campell
LEGAL-REP: Elliot M. Olstein, Raymond J. Lillie

ABSTRACT:
A process for introducing an expression vehicle (e.g., plasmids, retroviral vectors, **adenoviral vectors**) into cells, which comprises contacting the cells with the expression vehicle and a polyol. The polyol may be a polyoxalkylene block copolymer, such as a polyoxypropylene-polyoxyethylene block copolymer. The use of the polyol provides for greater efficiency of transduction of the expression vehicle.

15 Claims, 9 Drawing Figures

US PAT NO: 5,496,731 :IMAGE AVAILABLE: L3: 6 of 6
DATE ISSUED: Mar. 5, 1996
TITLE: Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy
INVENTOR: Hong-Ji Xu, 10 Moonseed Pl., The Woodlands, TX 77381
Shi-Xue Hu, 10 Moonseed Pl., The Woodlands, TX 77381
William F. Benedict, 21 E. Wedgewood Glen, The Woodlands, TX 77381
APPL-NO: 08/038,760
DATE FILED: Mar. 25, 1993
INT-CL: :6: C12N 15/86; C12N 15/85
US-CL-ISSUED: 435/320.1; 536/23.5; 514/44
US-CL-CURRENT: 435/320.1; 514/44; 536/23.5
SEARCH-FLD: 536/350, 23.5; 435/69.1, 320.1

REF-CITED:

U.S. PATENT DOCUMENTS

4,740,463	[illegible]84	Weinberg et al.	435/68.1
4,942,123	9/1987	Lee et al.	435/7.23
5,174,993	6/1990	Paoletti	424/199.1

FOREIGN PATENT DOCUMENTS

80426/91	7/1991	Australia
0259031	8/1987	European Patent Office
WO88/09387	5/1988	World Intellectual Property Organization
WO89/03429	8/1988	World Intellectual Property Organization
WO89/06703	1/1989	World Intellectual Property Organization
WO90/05180	10/1989	World Intellectual Property Organization
WO90/12807	4/1990	World Intellectual Property Organization
WO91/15580	4/1991	World Intellectual Property Organization
WO92/05272	9/1991	World Intellectual Property Organization

OTHER PUBLICATIONS

Ferrailo et al Protein Pharmacokinetics & Metabolism Chapt 1 pp. 1-34 1992 Plenum Press New York, New York.

Konrad Biological Barriers to Protein Delivery Cpt 14 pp. 409-435 1992 Plenum Press New York, New York.

Verma, Scientific American vol. 263(5) pp. 68-84, 1990.

Rosenfeld et al Cell vol. 68 pp. 143-155, 1992.

Karson et al. Jour. Rep. Medicine vol. 37 (6) pp. 500-514, Jun. 1992.

Af Trampe et al., 1983, Results Obtained in Treating Retinoblastoma patients with Diffrent Techniques at the Karolinska Hospital, Springer-Verlag pp. 529-533.

Ahlering et al., 1987, A New in Vivo Model to Study Invasion and Metastasis of Human Bladder Carcinoma, Cancer Research 47:6660-6665.

Akiyama et al., 1990, Marked alteration in phosphorylation of the RB protein during differentiation of human promyelocytic HL 60 cells, Oncogene 5:179-183.

Anderson, 1992, Human Gene Therapy, Science 256:808-813.

Ausubel et al., 1992, Short Protocols in Molecular Biology, Current Protocols in Molecular Biology, John Wiley and Jones, New York.

Baker et al., 1990, Suppression of Human Colorectal Carcinoma Cell Growth by Wild-Type p. 53, Science 249:912-915.

Ballester et al, 1990, The NF1 Locus Encodes a Protein Functionally Related to Mammalian GAP and Yeast IRA Proteins, Cell 63:851-859.

Banerjee et al., 1992, Changes in Growth and Tumorigenicity following Reconstitution of Retinoblastoma Gene Function in Various Human Cancer Cell Types by Microcell Transfer of Chromosome 13, Cancer Research 52:6297-6304.

Bayer et al., 1980, The Use of the Avidin-Biotin Complex as a Tool in Molecular Biology, Methods Biochem. Anal. 26:1-45.

Benedict et al., 1990, Role of the Retinoblastoma Gene in the Initiation and Progression of Human Cancer, J. Clin. Invest. 85:988-993.

Benoist et al., 1981, In vivo sequence requirements of the SV40 early promoter region, Nature 290:304-310.

Bookstein et al., 1991, Molecular Genetics of the Retinoblastoma Suppressor Gene, Crit. Rev. Oncog. 2(3):211-227.

Bookstein et al, 1990, Suppression of Tumorigenicity of Human Prostate Carcinoma Cells by Replacing a Mutated RB Gene, Science 247:712-715.

Brinster et al., 1982, Regulation of metallothionein-thymidine kinase fusion plasmids injected into mouse eggs, Nature 296:39-42.2.

Brown et al., 1984 Mechanism of activation of an N-ras gene in the human fibrosarcoma cell line HT1080, EMBO J. 3(6):1321-1326.

Buchkovich et al., 1989, The Retinoblastoma Protein is Phosphorylated during Specific [redacted] of the Cell Cycle, Cell 58:10[redacted]105.
Ceccoli et al., 19[redacted] Encapsulation of the UV-DNA Repa[redacted]nzyme T4 Endocuclease V in Liposomes and Delivery to Human Cells, Journal of Investigative Dermatology 93:190-194.
Chen et al., 1989, Phosphorylation of the Retinoblastoma Gene Product is Modulated during the Cell Cycle and Cellular Differentation, Cell 58:1193-1198.
Culver et al., 1992, In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors, Science 256:1550-1552.
Culver et al., 1991, Lymphocyte Gene Therapy, Human Gene Therapy 2:107-109.
Curiel et al., 1991, Adenovirus enhancement of transferrin-polysine-mediated gene delivery, Proc. Natl. Acad. Sci. USA 88:8850-8854.
Davies, 1992, Moving stright to the target, Nature genetics 358:519.
DeCaprio et al., 1989, The Product of the Retinoblastoma Suceptibility Gene Has Properties of a Cell Cycle Regulatory Element, Cell 58:1085-1095.
Diller et al., 1990, p53 Functions as a Cell Cycle Control Protein in Osteosarcomas, Molecular and Cellular Biology 10(11):5772-5781.
Durst et al., Papillomavirus sequences integrate near cellular oncogenes in some cervical carcinomas, Proc. Natl. Acad. Sci. USA 84(4):1070-1074.
Fearon et al., 1990, A Genetic Model for Colorectal Tumorigenesis, Cell 61:759-767.
Francois et al., Mar./Apr., The Costenbader Memorial Lecture Genesis and Genetics of Retinoblastoma, Journal of Pediatric Opthalmology and Strabismus 16(2):85-100.
Friend et al., 1987, Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: Organization of the sequence and its encoded protein, Proc. Natl. Acad. Sci. USA 84:9059-9063.
Furukawa et al., 1990, Expression and state of phosphorylation of the retinoblastoma susceptibility gene product in cycling and noncycling human hematopoietic cells, P.N.A.S. USA 87:2770-2774.
Gallie et al, 1991, The Genetics of Retinoblastoma: Relevance to the Patient, Pediatric Clinics of North America 38(2):299-315.
Gallie et al., 1992, How Do Retinoblastoma Tumours Form?, Eye 6:226-231.
Goodrich et al., 1992, Abrogation by c-myc of G1 phase arrest induced by RB protein but not by p53, Nature 360:177-179.
Goodrich et al., 1992, Expression of the Retinoblastoma Gene Product in Bladder carcinoma Cells Associates with a Low Frequency of Tumor Formation, Cancer Research 52:1968-1973.
Gunning et al., 1987, A human .beta.-actin expression vector system directs high-level accumulation of antisense transcripts, Proc. Natl. Acad. Sci. USA 84:4831-4835.
Hamel et al., 1992, Transcriptional Repression of the E2-Containing Promotors EllaE, c-myc, and RB1 by the Product of the RB1 Gene, Molecular and Cellular Biology 12(8):3431-3438.
Huang et al., 1988, Suppresion of the Neoplastic Phenotype by Replacement of the RB Gene in Human Cancer Cells, Science reports 242:1563-1566.
Jaffe et al., 1992, Adenovirus-mediated in vivo gene transfer and expression in normal rat liver, Nature genetics 1:372-378.
Karasuyama et al., 1989, Autocrine Growth and Tumorigenicity of Interleukin 2-Dependent Helper T Cells Transfected with IL-2 Gene, J. Exp. Med. 169:13.
Klessig et al., 1984, Introduction, Stable Integration, and Controlled Expression of a Chimeric Adenoirus Gene Whose Product Is Toxic to the Recipient Human Cell, Mol. Cell Biol. 4:1354-1362.
Knight et al., 1988, Antiviral Therapy with Small Particle Aerosols, European Journal of Clinical Microbiology and Infectious Diseases 7(6):721-731.
Kratzke et al., 1992, Functional Analysis at the Cys-706 Residue of the Retinoblastoma Protein, The Journal of Biological Chemistry 267(36):25998-26003.

Kutty et al., 1992, Heme oxygenase: expression in human retina and modulation by st[redacted]ents in a human retinoblastoma[redacted]ll model system, Oxford U[redacted]ersity Press 11(2):153-160.
Lee et al., 1990, Molecular biology of the Human Retinoblastoma Gene, Immunol Ser. 51:169-200.
Lee et al., 1987, The retinoblastoma susceptibility gene encodes a nuclear phosphoprotein associated with DNA binding activity, Nature 329:642-645.
Lemarchand et al., Adenovirus-mediated transfer of a recombinant human alpha.sub.1 -antitrypsin cDNA to human endothelial cells, P.N.A.S. USA 89:6482-6486.
Lin et al., 1992, Nasopharyngeal Carcinoma and Retinoblastoma Gene Expression, Laboratory Investigation 67(1):56-70.
Ludlow et al., 1989, SV40 Large T Antigen Binds Preferentially to an Underphosphorylated Member of the Retinoblastoma Suceptibility Gene Product Family, Cell 56:57-65.
Lynch et al., 1991, Production of High-Titer Helper Virus-Free Retroviral Vectors by Cocultivation of Packaging Cells with Different Host Ranges, J. Virol. 65:3887-3890.
Maniatis et al., 1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
Mannino et al., 1988, Liposome Mediated Gene Transfer, Biotechniques 6(7):682-690.
Marshall, 1991, Tumor Suppressor Genes, Cell 64:313-326.
McGee et al., 1989, Structure and partial genomic sequence of the human retinoblastoma susceptibility gene, Gene 80:119-128.
Mihara et al., 1989, Cell Cycle-Dependent regulation of Phosphorylation of the Human Retinoblastoma Gene Product, Science 246:1300-1303.
Miller, 1992, Human gene therapy comes of age, Nature 357:455-460.
Miller et al., 1986, Redesign of Retrovirus Packaging Cell Lines to Avoid Recombination Leading to Helper Virus Production, Molec. Cell Biol. 6(8):2895-2902.
Miller et al., 1985, Generation of Helper-Free Amphotropic Retroviruses That Transduce a Dominant-Acting , Methotrexate-Resistant Dihydrofolate Reductase Gene, Molec. Cell Biol. 5(3):431-437.
Miyanohara et al., 1988, Efficient expression of retroviral vector-transduced human low density lipoprotein (LDL) receptor-deficient rabbit fibroblasts in vitro, Proc. Natl. Acad. Sci. USA 85:6538-6542.
Murakami et al., 1991, Inactivation of the retinoblastoma gene in a human lung carcinoma cell line detected by single-strand conformation polymorphism analysis of the polymerase chain reaction product of cDNA, Oncogene 6:37-42.
Nabel et al., 1990, Site-Specific Gene Expression in Vivo by Direct Gene Transfer into the Arterial Wall, Science 249:1285-1288.
Newton et al., 1988, Vesicle-to-Cell Protein Transfer: Insertion of Band 3, the Erythrocyte Anion Transporter, into Lymphoid Cells, Biochemistry 27:4655-4659.
Riele et al., 1992, Highly efficient gene targeting in embryonic stem cells through homologous recombination with isogenic DNA constructs, P.N.A.S. USA 89:5128-5132.
Rosenfeld et al., 1992, In Vivo Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to the Airway Epithelium, Cell 68:143-155.
Schier, 1992, Conversations: Gene Therapy, The Cancer Bulletin 44(3)167.
Shew et al., 1990, C-terminal truncation of the retinoblastoma gene product leads to functional inactivation, P.N.A.S. USA 87:6-10.
Shew et al., 1989, Antibodies Detecting Abnormalities of the Retinoblastoma Susceptibility Gene Product (pp. 110-RB) in Osteosarcomas and Synovial Sarcomas, Ocogene Research 1:205-214.
Stein et al., 1990, Failure to Phosphorylate the Retinoblastoma Gene Product in Senescent Human Fibroblasts, Science 249:666-669.
Stone, 1992, Molecular `Surgery` for Brain Tumors, Science 256:1513.
Sugawara et al., 1991, Distribution of c-yes-1 gene product in various cells and tissues, Br. J. Cancer 63(4):508-513.

Takahashi et al., 1991, The retinoblastoma gene functions as a growth and tumor suppressor in human bladder carcinoma cells, Proc. Natl. Acad. Sci. USA 88:5257-5261.
Tanswell et al., 1990, Response of fetal rat lung fibroblasts to elevated oxygen concentrations after liposome-mediated augmentation of antioxidant enzymes, Biochimica et Biophysica Acta 1044:269-274.
Templeton et al., 1991, Nonfunctional mutants of the retinoblastoma protein are characterized by defects in phosphorylation, viral oncoprotein association, and nuclear tethering, Proc. Natl. Acad. Sci. USA 88:3033-3037.
Thompson, 1992, Stem-Cell Gene Therapy Moves Toward Approval, Science 255:1072.
Uzvolgyi et al., 1991, Reintroduction of a Normal Retinoblastoma Gene into Retinoblastoma and Osteosarcoma Cells Inhibits the Replication associated Function of SV40 Large T Antigen, Cell Growth & Differentiation 2:297-303.
Wagner et al., 1981, Nucleotide sequence of the thymidine kinase gene of herpes simplex virus type 1, Proc. Natl. Acad. Sci. USA 78(3):1441-1445.
Weinberg, 1991, Tumor Suppressor Genes, Science articles 254:1138-1146.
Weinberg, 1989, Oncogenes, Antioncogenes, and the Molecular Bases of Multistep Carcinogenesis, Cancer Research 49:3713-3721.
Weiss et al., 1985, RNA Tumor Viruses, Cold Spring Harbor, New York.
Whyte et al., 1988, Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product, Nature 334:124-129.
Wolfe et al., 1992, Herpesvirus vector gene transfer and express of .beta.-glucuronidase in the central nervous system of MPS VII mice, Nature Genetics 1:379-384.
Wu et al., 1991, Receptor-mediated Gene Delivery in Vivo: Partial Correction of Genetic Analbuminemia in Nagase Rats, J. Biol. Chem. 266:14338-14342.
Xu et al., 1991, Intraocular Tumor formation of RB Reconstituted reinoblastoma Cells, Cancer Research 51:4481-4485.
Xu et al., 1991, Lack of nuclear RB protein staining in G0/middle G1 cells: correlation to changes in total RB protein level, Oncogene 6:1139-1146.
Xu et al., 1989, The retinoblastoma susceptibility gene product: a characteristic pattern in normal cells and abnormal expression in malignant cells, Oncogene 4:807-812.
Yamada et al., 1985, Overproduction of the protein product of a nonselected foreign gene carried by an adenovirus vector, Proc. Natl. Acad. Sci. USA 82(11):3567-71.
Yamamoto et al., 1980, Identification of a Functional Promoter in the Long Terminal Repeat of Rous Sarcoma Virus, Cell 22:787-797.
Yokota et al., 1988, Altered expression of the retinoblastoma (RB) gene in small-cell carcinoma of the lung, Oncogene 3:471-475.
Zhou et al., 1993, Characterization of RB+ clones of RB reconstituted retinoblastoma and osteosarcoma cells, Proc. Am. Assoc. Cancer Res. 34:538 abstract No. 3214.

ART-UNIT: 185
PRIM-EXMR: Richard A. Schwartz
ASST-EXMR: David B. Schmickel

ABSTRACT:
The present invention relates to a broad-spectrum tumor suppressor gene and the protein expressed by that gene in appropriate host cells. The protein is a second in-frame AUG codon-initiated retinoblasoma protein of about 94 kD relative molecular mass. The present invention also relates to methods of treating a mammal having a disease or disorder characterized by abnormal cellular proliferation, such as a tumor or cancer and methods of treating abnormally proliferating cells, such as tumor or cancer cells. Treatment is accomplished by inserting a host cell compatible p94.sup.RB expression vector or an effective amount of p94.sup.RB protein into a cell or cells in need of treatment.

12 Claims, 26 Drawing Figures

ILIGHT set on as ''
HILIGHT set on as ''
? begin 5,6,55,154,155,156,312,399,biotech,biosci

```
   Set  Items  Description
      ---  -----  -----------
? s adenovir? and superoxide dismutase?

Processed  30 of  56 files ...
Processing
Completed processing all files
          122788  ADENOVIR?
           51318  SUPEROXIDE DISMUTASE?
      S1      45  ADENOVIR? AND SUPEROXIDE DISMUTASE?
? rd s1

>>>Duplicate detection is not supported for File 42.
>>>Duplicate detection is not supported for File 140.
>>>Duplicate detection is not supported for File 187.
>>>Duplicate detection is not supported for File 189.
>>>Duplicate detection is not supported for File 286.
>>>Duplicate detection is not supported for File 428.
>>>Duplicate detection is not supported for File 429.
>>>Duplicate detection is not supported for File 441.
>>>Duplicate detection is not supported for File 446.
>>>Duplicate detection is not supported for File 449.
>>>Duplicate detection is not supported for File 452.
>>>Duplicate detection is not supported for File 455.
>>>Duplicate detection is not supported for File 456.

>>>Records from unsupported files will be retained in the RD set.
...completed examining records
      S2      16  RD S1 (unique items)
? d s2/3/1-16

      Display 2/3/1     (Item 1 from file: 154)
DIALOG(R)File 154:MEDLINE(R)
(c) format only 1997 Knight-Ridder Info. All rts. reserv.

09165977   97298020
  Intrastriatal grafts of embryonic mesencephalic rat neurons genetically
modified using an adenovirus encoding human Cu/Zn superoxide
dismutase.
  Barkats M; Nakao N; Grasbon-Frodl EM; Bilang-Bleuel A; Revah F; Mallet J;
Brundin P
  Laboratoire de Genetique Moleculaire de la Neurotransmission et des
Processus Neurodegeneratifs, UMR CNRS C9923, Hopital de la Pitie
Salpetriere, Paris, France.
  Neuroscience (UNITED STATES) Jun 1997, 78 (3) p703-13, ISSN 0306-4522
Journal Code: NZR
  Languages: ENGLISH
  Document type: JOURNAL ARTICLE

                                - end of record -
?

      Display 2/3/2     (Item 2 from file: 154)
DIALOG(R)File 154:MEDLINE(R)
(c) format only 1997 Knight-Ridder Info. All rts. reserv.

09058853   97238105
  Ca2+ and reactive oxygen species in staurosporine-induced neuronal
apoptosis.
```

Prehn JH; Jordan J; Chadge GD; Preis E; Galindo MF; Roos RP; Krieglstein J; Miller RJ
Department of P[redacted]acology and Toxicology, Philipps[redacted]iversity, Marburg, Germany.
J Neurochem (UNITED STATES) Apr 1997, 68 (4) p1679-85, ISSN 0022-3042 Journal Code: JAV
Contract/Grant No.: MH40165, MH, NIMH; NS21442, NS, NINDS
Languages: ENGLISH
Document type: JOURNAL ARTICLE

- end of record -

?

Display 2/3/3 (Item 3 from file: 154)
DIALOG(R)File 154:MEDLINE(R)

08838139 97059139
Superoxide-mediated actin response in post-hypoxic endothelial cells.
Crawford LE; Milliken EE; Irani K; Zweier JL; Becker LC; Johnson TM; Eissa NT; Crystal RG; Finkel T; Goldschmidt-Clermont PJ
Division of Cardiology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.
J Biol Chem (UNITED STATES) Oct 25 1996, 271 (43) p26863-7, ISSN 0021-9258 Journal Code: HIV
Contract/Grant No.: HL52315, HL, NHLBI
Languages: ENGLISH
Document type: JOURNAL ARTICLE

- end of record -

?

Display 2/3/4 (Item 4 from file: 154)
DIALOG(R)File 154:MEDLINE(R)

08776986 96290653
An **adenovirus** encoding CuZnSOD protects cultured striatal neurones against glutamate toxicity.
Barkats M; Bemelmans AP; Geoffroy MC; Robert JJ; Loquet I; Horellou P; Revah F; Mallet J
Laboratoire mixte Rhone-Poulenc-RORER/CNRS C9923, CERVI, Hopital de la Pitie Salpetriere, Paris, France.
Neuroreport (ENGLAND) Jan 31 1996, 7 (2) p497-501, ISSN 0959-4965 Journal Code: A6M
Languages: ENGLISH
Document type: JOURNAL ARTICLE

- end of record -

?

Display 2/3/5 (Item 5 from file: 154)
DIALOG(R)File 154:MEDLINE(R)

08607307 96239197
Mechanisms of unusually high antioxidant activity of RSV-SR-transformed cells and of its suppression by activated p21ras.
Deichman GI; Kashkina LM; Mizenina OA; Gorojanskaya EG; Nikiforov MA; Gudkov AV; Dyakova NA; Komelkov AV; Prilutskaya MO; Kushlinsky NE; Tatosyan AG
Institute of Carcinogenesis, Cancer Research Center of Russian Academy of Medical Sciences, Moscow, Russia.
Int J Cancer (UNITED STATES) Jun 11 1996, 66 (6) p747-52, ISSN 0020-7136 Journal Code: GQU

Contract/Grant No.: R21 CA62045, CA, NCI
Languages: ENGLIS[redacted]
Document type: J[redacted] ARTICLE

- end of record -

?

Display 2/3/6 (Item 6 from file: 154)
DIALOG(R)File 154:MEDLINE(R)

08593249 96226070
Protective effect of transforming growth factor-beta 1 on beta-amyloid neurotoxicity in rat hippocampal neurons.
Prehn JH; Bindokas VP; Jordan J; Galindo MF; Ghadge GD; Roos RP; Boise LH ; Thompson CB; Krajewski S; Reed JC; Miller RJ
Department of Pharmacological and Physiological Sciences, University of Chicago, Illinois 60637, USA.
Mol Pharmacol (UNITED STATES) Feb 1996, 49 (2) p319-28, ISSN 0026-895X Journal Code: NGR
Contract/Grant No.: DA02121, DA, NIDA; DA02575, DA, NIDA; MH40165, MH, NIMH; +
Languages: ENGLISH
Document type: JOURNAL ARTICLE

- end of record -

?

Display 2/3/7 (Item 7 from file: 154)
DIALOG(R)File 154:MEDLINE(R)

08306402 95327064
Expression of human copper/zinc-superoxide dismutase inhibits the death of rat sympathetic neurons caused by withdrawal of nerve growth factor.
Jordan J; Ghadge GD; Prehn JH; Toth PT; Roos RP; Miller RJ
Department of Pharmacological and Physiological Sciences, University of Chicago, Illinois 60637, USA.
Mol Pharmacol (UNITED STATES) Jun 1995, 47 (6) p1095-1100, ISSN 0026-895X Journal Code: NGR
Contract/Grant No.: DA02575, DA, NIDA; DA02121, DA, NIDA; MH40165, MH, NIMH; +
Languages: ENGLISH
Document type: JOURNAL ARTICLE

- end of record -

?

Display 2/3/8 (Item 8 from file: 154)
DIALOG(R)File 154:MEDLINE(R)

07054168 91346113
The E1b oncogene of **adenovirus** confers cellular resistance to cytotoxicity of tumor necrosis factor and monoclonal anti-Fas antibody.
Hashimoto S; Ishii A; Yonehara S
Meiji Institute of Health Science, Odawara, Japan.
Int Immunol (ENGLAND) Apr 1991, 3 (4) p343-51, ISSN 0953-8178 Journal Code: AY5
Languages: ENGLISH
Document type: JOURNAL ARTICLE

- end of record -

?

Display 2/3/9 (Item 9 from file: 154)
DIALOG(R)File 154: [redacted] (R)
(c) format only 1[redacted] Knight-Ridder Info. All rts. rese[redacted]

05577541 89077686
Melanin synthesis and the action of L-dopa and 3,4-dihydroxybenzylamine in human melanoma cells.
Kable EP; Parsons PG
Queensland Institute of Medical Research, Herston, Australia.
Cancer Chemother Pharmacol (GERMANY, WEST) 1989, 23 (1) p1-7, ISSN 0344-5704 Journal Code: C9S
Languages: ENGLISH
Document type: JOURNAL ARTICLE

- end of record -

?

Display 2/3/10 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

10153072 EMBASE No: 96339142
Adenovirus for neurodegenerative diseases: In vivo strategies and ex vivo gene therapy using human neural progenitors
Sabate O.; Barkats M.; Buc-Caron M.-H.; Castel-Barthe M.-N.; Finiels F.; Horellou P.; Revah F.; Mallet J.
CNRS C 9923, LGMNPD (LGN), Hopital de la Pitie, 83 Boulevard de l'Hopital, 75013 Paris France
Clinical Neuroscience (USA) , 1995/96, 3/5 (317-321) CODEN: CINUE ISSN: 1065-6766
LANGUAGES: English SUMMARY LANGUAGES: English

- end of record -

?

Display 2/3/11 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

5901081 EMBASE No: 85146591
Modification of dopa toxicity in human tumour cells
Parsons P.G.
Queensland Institute of Medical Research, Herston, Qld. 4006 USA
BIOCHEM. PHARMACOL. (ENGLAND) , 1985, 34/10 (1801-1807) CODEN: BCPCA
LANGUAGES: ENGLISH

- end of record -

?

Display 2/3/12 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

1210120 EMBASE No: 78390333
Properties and products of the degradation of DNA by bleomycin and iron (II)
Sausville E.A.; Stein R.W.; Peisach J.; Horwitz S.B.
Dept. Molec. Pharmacol., Albert Einstein Coll. Med., Bronx, N.Y. 10461 USA
BIOCHEMISTRY (WASH.) (USA) , 1978, 17/14 (2746-2754) CODEN: BICHA
LANGUAGES: ENGLISH

- end of record -

?

Display 2/3/13 (Item 1 from file: 71)
DIALOG(R)File 71: [redacted]R BIOBASE
(c) 1997 Elsevier [redacted]ience B.V. All rts. reserv.

00743074 97249226
Mutant superoxide dismutase-1-linked familial amyotrophic lateral sclerosis: Molecular mechanisms of neuronal death and protection
Ghadge G.D.; Lee J.P.; Bindokas V.P.; Jordan J.; Ma L.; Miller R.J.; Roos R.P.
ADDRESS: Dr. R.P. Roos, Department or Neurology, MC 2030, University of Chicago, 5841 South Maryland Avenue, Chicago, IL 60637, United States
Journal: Journal of Neuroscience, 17/22 (8756-8766), 1997, United States
CODEN: JNRSD
ISSN: 0270-6474
DOCUMENT TYPE: Article
LANGUAGES: English SUMMARY LANGUAGES: English
NO. OF REFERENCES: 40

- end of record -
?

Display 2/3/14 (Item 2 from file: 71)
DIALOG(R)File 71:ELSEVIER BIOBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

00572240 97075064
Casup 2sup + and reactive oxygen species in staurosporine-induced neuronal apoptosis
Prehn J.H.M.; Jordan J.; Ghadge G.D.; Preis E.; Galindo M.F.; Roos R.P.; Krieglstein J.; Miller R.J.
ADDRESS: Dr. J.H.M. Prehn, Pharmacology/Toxicology Department, Philipps-University, Ketzerbach 63, 35032 Marburg, Germany
Journal: Journal of Neurochemistry, 68/4 (1679-1685), 1997, United States
CODEN: JONRA
ISSN: 0022-3042
DOCUMENT TYPE: Article
LANGUAGES: English SUMMARY LANGUAGES: English
NO. OF REFERENCES: 52

- end of record -
?

Display 2/3/15 (Item 1 from file: 315)
DIALOG(R)File 315:ChemEng & Biotec Abs
(c)1997 RoySocChm,DECHEMA,FizChemie. All rts. reserv.

404436 CEABA Accession No.: 28-01-001636 DOCUMENT TYPE: Patent
Title: **Adenovirus** including a gene coding for a superoxide dismutase.
AUTHOR: Barkats, M. ; Mallet, J. ; Perricaudet, M. ; Revah, F.
CORPORATE SOURCE: Rhone-Poulenc Rorer S.A. F-92160 Antony France
CODEN: PIXXD2
PATENT NUMBER: WO 9600790
PUBLICATION DATE: 11 Jan 1996 (960111) LANGUAGE: English
PRIORITY PATENT APPLICATION(S) & DATE(S): FR 9408029 (940629)

- end of record -
?

Display 2/3/16 (Item 1 from file: 434)
DIALOG(R)File 434:Scisearch(R) Cited Ref Sci
(c) 1997 Inst for Sci Info. All rts. reserv.

12214631 Genuine Article#: KV111 No. References: 60
Title: HIV-1 PROMOTER ACTIVATION FOLLOWING AN OXIDATIVE STRESS MEDIATED BY

SINGLET OXYGEN
Author(s): LEGRAND [redacted]; HOEBEKE M; VAIRA D; RENTIER [redacted] PIETTE J
Corporate Source: [redacted]V LIEGE,INST PATHOL B23,VIROL LAB [redacted]4000 LIEGE//BELGIUM/; UNIV LIEGE,INST PATHOL B23,VIROL LAB/B-4000 LIEGE//BELGIUM/; UNIV LIEGE,INST PHYS B5/B-400 LIEGE//BELGIUM/
Journal: JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY, 1993, V17, N3 (MAR), P229-237
ISSN: 1011-1344
Language: ENGLISH Document Type: ARTICLE (Abstract Available)

- end of display -

?

>>>Page beyond end of display invalid

-more-

```
? s gene therapy and fail? and review?

Processing
Processed  10 of  56 files ...
Processing
Processed  20 of  56 files ...
Processing
Processed  40 of  56 files ...
Completed processing all files
           35499  GENE THERAPY
         2399694  FAIL?
         5411978  REVIEW?
      S3     163  GENE THERAPY AND FAIL? AND REVIEW?
? s s3 and adenovir?

Processed  40 of  56 files ...
Processing
Completed processing all files
             163  S3
          122788  ADENOVIR?
      S4      27  S3 AND ADENOVIR?
? rd s4

>>>Duplicate detection is not supported for File 42.
>>>Duplicate detection is not supported for File 140.
>>>Duplicate detection is not supported for File 187.
>>>Duplicate detection is not supported for File 189.
>>>Duplicate detection is not supported for File 286.
>>>Duplicate detection is not supported for File 428.
>>>Duplicate detection is not supported for File 429.
>>>Duplicate detection is not supported for File 441.
>>>Duplicate detection is not supported for File 446.
>>>Duplicate detection is not supported for File 449.
>>>Duplicate detection is not supported for File 452.
>>>Duplicate detection is not supported for File 455.
>>>Duplicate detection is not supported for File 456.

>>>Records from unsupported files will be retained in the RD set.
...completed examining records
      S5      23  RD S4 (unique items)
? d s5/3/1-23

      Display 5/3/1     (Item 1 from file: 73)
DIALOG(R)File  73:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

10503808   EMBASE No: 97313634
  Gene therapy for renal diseases
  Lien Y.-H.; Lai L.-W.
  Dr.  Y.-H.  Lien, Section of Renal Disease, Department of Medicine, Univ.
of Arizona Hlth. Sci. Center, Tucson, AZ 85724  USA
  Kidney  International, Supplement (USA) , 1997, 51/61 (S-85-S-88)  CODEN:
KISUD   ISSN: 0098-6577
  DOCUMENT TYPE: Journal
  LANGUAGES: English   SUMMARY LANGUAGES: English
  NUMBER OF REFERENCES: 35
```

- end of record -

?

Display 5/3/2 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE

10260610 EMBASE No: 97072654
Genetic therapy: Past, present, and future
Flotte T.R.; Ferkol T.W.
USA
Pediatric Clinics of North America (USA) , 1997, 44/1 (153-178) CODEN: PCNAA ISSN: 0031-3955
DOCUMENT TYPE: Journal
LANGUAGES: English SUMMARY LANGUAGES: English
NUMBER OF REFERENCES: 183

- end of record -

?

Display 5/3/3 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE

10157803 EMBASE No: 96313015
Gene therapy in the United States: A five-year status report
Ross G.; Erickson R.; Knorr D.; Motulsky A.G.; Parkman R.; Samulski J.; Straus S.E.; Smith B.R.
Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520-8035 USA
Human Gene Therapy (USA) , 1996, 7/14 (1781-1790) CODEN: HGTHE ISSN: 1043-0342
LANGUAGES: English SUMMARY LANGUAGES: English

- end of record -

?

Display 5/3/4 (Item 4 from file: 73)
DIALOG(R)File 73:EMBASE

10119095 EMBASE No: 96310110
Molecular therapy for renal diseases
Lipkowitz M.S.; Klotman M.E.; Bruggeman L.A.; Nicklin P.; Hanss B.; Rappaport J.; Klotman P.E.
Department of Medicine, Mount Sinai School of Medicine, Box 1243, One Gustave Levy Place, New York, NY 10029 USA
American Journal of Kidney Diseases (USA) , 1996, 28/4 (475-492) CODEN: AJKDD ISSN: 0272-6386
LANGUAGES: English SUMMARY LANGUAGES: English

- end of record -

?

Display 5/3/5 (Item 5 from file: 73)
DIALOG(R)File 73:EMBASE

9813801 EMBASE No: 95366288
Gene therapy for cystic fibrosis: Challenges and future directions
Wilson J.M.
Institute for Human Gene Therapy, 204 Wistar Institute, 3601 Spruce St., Philadelphia, PA 19104-4268 USA
Journal of Clinical Investigation (USA) , 1995, 96/6 (2547-2554) CODEN: JCINA ISSN: 0021-9738
LANGUAGES: English

- end of record -

?

Display 5/3/6 (Item 6 from file: 73)
DIALOG(R)File 73:EMBASE

9504176 EMBASE No: 95075954
Gene therapy for cystic fibrosis using cationic liposome mediated gene transfer: A phase I trial of safety and efficacy in the nasal airway
Sorscher E.J.; Logan A.J.; Frizzell R.A.; Lyrene R.K.; Bebok Z.; Dong J.Y.; Duvall M.D.; Felgner P.L.; Matalon S.; Walker L.; Wiatrak B.J.
University of Alabama at Birmingham, Children's Hospital of Alabama, Birmingham, AL USA
Human Gene Therapy (USA) , 1994, 5/10 (1259-1270) CODEN: HGTHE ISSN: 1043-0342
LANGUAGES: English SUMMARY LANGUAGES: English

- end of record -

?

Display 5/3/7 (Item 7 from file: 73)
DIALOG(R)File 73:EMBASE

9193736 EMBASE No: 94146724
The molecular and cellular biology of heart **failure**
Carter L.F.; Rubin S.A.
Cardiology (111c), Veterans Admin Medical Center, 5901 East Seventh Street, Long Beach, CA 90822 USA
CURR. OPIN. CARDIOL. (United Kingdom) , 1994, 9/3 (264-271) CODEN: COPCE ISSN: 0268-4705
LANGUAGES: English SUMMARY LANGUAGES: English

- end of record -

?

Display 5/3/8 (Item 8 from file: 73)
DIALOG(R)File 73:EMBASE

9169006 EMBASE No: 94116344
Coronary restenosis and gene therapy
Mazur W.; Ali N.M.; Raizner A.E.; French B.A.
Section of Cardiology, Department of Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030 USA
TEX. HEART INST. J. (USA) , 1994, 21/1 (104-111) CODEN: THIJD ISSN: 0730-2347
LANGUAGES: English SUMMARY LANGUAGES: English

- end of record -

?

Display 5/3/9 (Item 1 from file: 71)
DIALOG(R)File 71:ELSEVIER BIOBASE

00738840 97243664
Prevention of vein graft **failure**: Potential applications for gene therapy
Baker A.H.; Mehta D.; George S.J.; Angelini G.D.
ADDRESS: A.H. Baker, Bristol Heart Institute, Bristol Royal Infirmary, Bristol BS2 8HW, United Kingdom
EMAIL: a.h.baker@bristol.ac.uk

Journal: Cardiovascular Research, 35/3 (442-450), 1997, Netherlands
CODEN: CVREA
ISSN: 0008-6363
PUBLISHER ITEM IDENTIFIER: S0008636397001168
DOCUMENT TYPE: Review
LANGUAGES: English SUMMARY LANGUAGES: English
NO. OF REFERENCES: 74

- end of record -

?

Display 5/3/10 (Item 1 from file: 149)
DIALOG(R)File 149:IAC(SM)Health&Wellness DB(SM)

01679020 SUPPLIER NUMBER: 19230136 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Lung cancer.(Science, Medicine, and the Future)
Sethi, Tariq
British Medical Journal, v314, n7081, p652(4)
March 1, 1997
PUBLICATION FORMAT: Magazine/Journal ISSN: 0959-8146 LANGUAGE: English
RECORD TYPE: Fulltext; Abstract TARGET AUDIENCE: Professional
WORD COUNT: 2801 LINE COUNT: 00245

- end of record -

?

Display 5/3/11 (Item 2 from file: 149)
DIALOG(R)File 149:IAC(SM)Health&Wellness DB(SM)

01676744 SUPPLIER NUMBER: 17715890 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Development and application of herpes simplex virus vectors for human gene therapy.
Glorioso, J.C.; DeLuca, N.A.; Fink, D.J.
Annual Review of Microbiology, v49, p675(36)
Annual, 1995
PUBLICATION FORMAT: Magazine/Journal ISSN: 0066-4227 LANGUAGE: English
RECORD TYPE: Fulltext; Abstract TARGET AUDIENCE: Academic
WORD COUNT: 16425 LINE COUNT: 01336

- end of record -

?

Display 5/3/12 (Item 3 from file: 149)
DIALOG(R)File 149:IAC(SM)Health&Wellness DB(SM)

01631504 SUPPLIER NUMBER: 18628120 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb.(plasmid human vascular endothelial growth factor)(Early Reports)
Isner, Jeffrey M.; Pieczek, Ann; Schainfeld, Robert; Blair, Richard; Haley, Laura; Asahara, Takayuki; Rosenfield, Kenneth; Razvi, Syed; Walsh, Kenneth; Symes, James F.
The Lancet, v348, n9024, p370(5)
August 10, 1996
PUBLICATION FORMAT: Magazine/Journal ISSN: 0099-5355 LANGUAGE: English
RECORD TYPE: Fulltext; Abstract TARGET AUDIENCE: Professional
WORD COUNT: 3057 LINE COUNT: 00257

- end of record -

?

Display 5/3/13 (Item 4 from file: 149)

DIALOG(R)File 149:IAC(SM)Health&Wellness DB(SM)
(c) 1997 Info Acce[redacted]All rts. reserv.

01532789 SUPPLIER NUMBER: 17246660 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Curing disease through human gene therapy.(Pamphlet)
Pamphlet by: National Heart, Lung, and Blood Institute, p1(38)
July, 1993
DOCUMENT TYPE: Pamphlet PUBLICATION FORMAT: Pamphlet LANGUAGE: English
RECORD TYPE: Fulltext TARGET AUDIENCE: Consumer
WORD COUNT: 7722 LINE COUNT: 00616

- end of record -

?

Display 5/3/14 (Item 5 from file: 149)
DIALOG(R)File 149:IAC(SM)Health&Wellness DB(SM)
(c) 1997 Info Access Co. All rts. reserv.

01489566 SUPPLIER NUMBER: 15795484 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Expert: next two years critical for antiviral gene therapies. (Flossie Wong-Staal, X International Conference on AIDS)
DeNoon, Daniel J.
AIDS Weekly, p2(5)
August 29, 1994
PUBLICATION FORMAT: Newsletter ISSN: 1069-1456 LANGUAGE: English
RECORD TYPE: Fulltext TARGET AUDIENCE: Professional
WORD COUNT: 2422 LINE COUNT: 00235

- end of record -

?

Display 5/3/15 (Item 6 from file: 149)
DIALOG(R)File 149:IAC(SM)Health&Wellness DB(SM)
(c) 1997 Info Access Co. All rts. reserv.

01481560 SUPPLIER NUMBER: 15414110 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Genes, dreams, and cancer. (gene therapy for cancer) (Current Issues in Cancer, part 8)
Sikora, Karol
British Medical Journal, v308, n6938, p1217(5)
May 7, 1994
PUBLICATION FORMAT: Magazine/Journal ISSN: 0959-8146 LANGUAGE: English
RECORD TYPE: Fulltext; Abstract TARGET AUDIENCE: Professional
WORD COUNT: 2588 LINE COUNT: 00306

- end of record -

?

Display 5/3/16 (Item 7 from file: 149)
DIALOG(R)File 149:IAC(SM)Health&Wellness DB(SM)
(c) 1997 Info Access Co. All rts. reserv.

01476996 SUPPLIER NUMBER: 14975260 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Cellular engineering and gene therapy strategies for insulin replacement in diabetes.
Newgard, Christopher B.
Diabetes, v43, n3, p341(10)
March, 1994
PUBLICATION FORMAT: Magazine/Journal ISSN: 0012-1797 LANGUAGE: English
RECORD TYPE: Fulltext TARGET AUDIENCE: Professional
WORD COUNT: 7818 LINE COUNT: 00803

- end of record -

?

Display 5/3/17 (Item 8 from file: 149)
DIALOG(R)File 149: Health&Wellness DB(SM)
(c) 1997 Info Acce Co. All rts. reserv.

01438071 SUPPLIER NUMBER: 14754403 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Progress toward human gene therapy.
Morsy, Manal A.; Mitani, Kohnosuke; Clemens, Paula; Caskey, C. Thomas
JAMA, The Journal of the American Medical Association, v270, n19, p2338(8)
Nov 17, 1993
PUBLICATION FORMAT: Magazine/Journal ISSN: 0098-7484 LANGUAGE: English
RECORD TYPE: Fulltext; Abstract TARGET AUDIENCE: Professional
WORD COUNT: 9037 LINE COUNT: 00777

- end of record -

?

Display 5/3/18 (Item 9 from file: 149)
DIALOG(R)File 149:IAC(SM)Health&Wellness DB(SM)
(c) 1997 Info Access Co. All rts. reserv.

01421140 SUPPLIER NUMBER: 14003767 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Molecular targets of gene transfer therapy for HIV infection.
Buchschacher, Gary L., Jr.
JAMA, The Journal of the American Medical Association, v269, n22, p2880(7)
June 9, 1993
PUBLICATION FORMAT: Magazine/Journal ISSN: 0098-7484 LANGUAGE: English
RECORD TYPE: Fulltext; Abstract TARGET AUDIENCE: Professional
WORD COUNT: 7338 LINE COUNT: 00611

- end of record -

?

Display 5/3/19 (Item 10 from file: 149)
DIALOG(R)File 149:IAC(SM)Health&Wellness DB(SM)
(c) 1997 Info Access Co. All rts. reserv.

01412277 SUPPLIER NUMBER: 13427568 (USE FORMAT 7 OR 9 FOR FULL TEXT)
The pace of human gene transfer research quickens. (From the National Institutes of Health)
Healy, Bernadine
JAMA, The Journal of the American Medical Association, v269, n5, p567(1)
Feb 3, 1993
PUBLICATION FORMAT: Magazine/Journal ISSN: 0098-7484 LANGUAGE: English
RECORD TYPE: Fulltext TARGET AUDIENCE: Professional
WORD COUNT: 982 LINE COUNT: 00081

- end of record -

?

Display 5/3/20 (Item 11 from file: 149)
DIALOG(R)File 149:IAC(SM)Health&Wellness DB(SM)
(c) 1997 Info Access Co. All rts. reserv.

01376664 SUPPLIER NUMBER: 14018048 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Gene transfer and gene therapy. (research and treatment applications)
Nielsen, David A.; Goldman, David
Alcohol Health & Research World, v16, n4, p304(8)
Fall, 1992
PUBLICATION FORMAT: Magazine/Journal ISSN: 0090-838X LANGUAGE: English
RECORD TYPE: Fulltext; Abstract TARGET AUDIENCE: Academic; Professional
WORD COUNT: 5709 LINE COUNT: 00486

- end of record -

?

Display 5/3/21 (Item 12 from file: 149)
DIALOG(R)File 149: [redacted] Health&Wellness DB(SM)
(c) 1997 Info Acce[redacted]Co. All rts. reserv.

01357490 SUPPLIER NUMBER: 12182780 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Cystic fibrosis: molecular biology and therapeutic implications. (Biotech Special Report: Molecular Advances)
Collins, Francis S.
Science, v256, n5058, p774(6)
May 8, 1992
PUBLICATION FORMAT: Magazine/Journal ISSN: 0036-8075 LANGUAGE: English
RECORD TYPE: Fulltext; Abstract TARGET AUDIENCE: Academic
WORD COUNT: 6227 LINE COUNT: 00504

- end of record -

?

Display 5/3/22 (Item 13 from file: 149)
DIALOG(R)File 149:IAC(SM)Health&Wellness DB(SM)
(c) 1997 Info Access Co. All rts. reserv.

01355683 SUPPLIER NUMBER: 12141705 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Gene therapy for cancer. (**review** article)(includes glossary)
Gutierrez, Andres A.; Lemoine, Nick R.; Sikora, Karol
The Lancet, v339, n8795, p715(7)
March 21, 1992
PUBLICATION FORMAT: Magazine/Journal ISSN: 0099-5355 LANGUAGE: English
RECORD TYPE: Fulltext; Abstract TARGET AUDIENCE: Professional
WORD COUNT: 4021 LINE COUNT: 00446

- end of record -

?

Display 5/3/23 (Item 14 from file: 149)
DIALOG(R)File 149:IAC(SM)Health&Wellness DB(SM)
(c) 1997 Info Access Co. All rts. reserv.

01249601 SUPPLIER NUMBER: 09213094 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Cystic fibrosis: towards the ultimate therapy, slowly. (editorial)
The Lancet, v336, n8725, p1224(2)
Nov 17, 1990
DOCUMENT TYPE: editorial PUBLICATION FORMAT: Magazine/Journal ISSN: 0099-5355 LANGUAGE: English RECORD TYPE: Fulltext; Abstract
TARGET AUDIENCE: Professional
WORD COUNT: 691 LINE COUNT: 00075

- end of display -

?

>>>Page beyond end of display invalid